Belgian Cancer Registry

CANCER FACT SHEET 2024
THYROID CANCER
ICD-10 C73

CONCEPTS AND ABBREVIATIONS

Absolute numbers (N): The number of newly registered cancer diagnoses observed for a given period of time. All figures and numbers in this cancer fact sheet are based on diagnoses of Belgian residents.

Average Annual Percentage Change (AAPC): The average relative chance in incidence risk from one year to the next. For example an AAPC of 1.05 (a 5% increase) applied to a cancer risk of 200/100,000 results in a risk of 210/100,000 one year later (=200*1.05) and 255/100,000 over 5 years (=200*$(1.05)^5$).

Crude Rate (CR): The crude rate is obtained by dividing the absolute number of diagnoses (N) by the corresponding population size at risk (N/100,000).

ESR2013: Incidence rates standardised to the 2013 revised European Standard Population (ESP): Standardisation is necessary to accommodate for differences in population size and age distribution (over time or among regions). An important factor in interpreting trends in cancer incidence is population ageing, as cancer is an age-dependent disease. For a higher proportion of elderly people in the population, a higher total number of cancer diagnoses can be expected for the same cancer risk. When only absolute numbers (N) or Crude Rate (CR) results are used, a misleading picture of the actual changes in the risk of a cancer diagnosis could be obtained. Therefore, direct standardisation is necessary to evaluate the evolution of the risk of cancer diagnosis over time or among regions.

Net survival: Often also called the relative survival, is an estimate of the survival probability when other causes of death beside the cancer type(s) under study are excluded. As examples of other causes of death, patients with the cancer type(s) under study could also die because of an accident or unrelated cardiac conditions, etc. Net survival may exceed 100%, this occurs when the observed survival probability for patients with the cancer type(s) under study is higher than the one for the matched general population (no excess mortality due to cancer).

The net survival estimation was based on the regional lifetables 2024, obtained from Statbel.

Stage: Cancers are reported with a stage, labelled with a Roman numeral with IV being the most advanced stage. Stage is based on the T-category (extent of the tumour), the N-category (absence or presence and extent of the regional lymph node metastasis) and the M-category (absence or presence of distant metastasis). Stage is reported as clinical and pathological stage and as a combination of both clinical and pathological stage with priority given to the pathological stage. Clinical information about distant metastases (cM) will always be taken into account, and in case of neo-adjuvant therapy, priority is given to the clinical stage. If stage is unknown, not applicable or not submitted to the Belgian Cancer Registry, the stage is reported as 'unregistered stage'. Stage is reported according to the TNM 8th edition: J.D. Brierley, M.K. Gospodarowicz, Ch. Wittekind. TNM Classification of Malignant Tumours, 8th edition: UICC, 2017.

95% CI: 95% Confidence Intervals are indicated with a shaded band or whiskers in the figures. The 95% CI is a range of values that has 95% chance to contain the true mean value.

Belgian Cancer Registry

TABLE OF CONTENTS

1. CANCER INCIDENCE 5

1.1. Thyroid cancer incidence: by region 5

1.1.1. Thyroid cancer incidence by region and sex: number of new diagnoses, age-specific, crude and age-standardised incidence rates, 2024 5

1.2. Thyroid cancer incidence: by tumour stage 7

1.2.1. Thyroid cancer incidence by clinical stage (cStage), sex and age group: number of new diagnoses, crude and age-standardised incidence rates, 2024 7

1.2.2. Thyroid cancer incidence by pathological stage (pStage), sex and age group: number of new diagnoses, crude and age-standardised incidence rates, 2024 7

1.2.3. Thyroid cancer incidence by stage, sex and age group: number of new diagnoses, crude and age-standardised incidence rates, 2024 8

1.3. Thyroid cancer incidence: by tumour type 9

1.3.1. Thyroid cancer incidence by type, sex and age group: number of new diagnoses, crude and age-standardised incidence rates, 2024 9

1.4. Thyroid cancer incidence: by tumour type and tumour stage 10

1.4.1. Thyroid cancer incidence by type, stage, sex and age group: number of new diagnoses, crude and age-standardised incidence rates, 2024 10

2. CANCER INCIDENCE TRENDS 12

2.1. Thyroid cancer incidence trends: by region 12

2.1.1. Thyroid cancer incidence trends in males, by region: number of new diagnoses, crude and age-standardised incidence rates, including average annual percentage change, 2004-2024 12

2.1.2. Thyroid cancer incidence trends in females, by region: number of new diagnoses, crude and age-standardised incidence rates, including average annual percentage change, 2004-2024 14

2.2. Thyroid cancer incidence trends: by tumour stage 15

2.2.1. Thyroid cancer incidence trends by stage and sex: number of new diagnoses, crude and age-standardised incidence rates, 2020-2024, including average annual percentage change from 2004 onwards 15

2.3. Thyroid cancer incidence trends: by tumour type 17

2.3.1. Thyroid cancer incidence trends in males by type: number of new diagnoses, crude and age-standardised incidence rates, including average annual percentage change, 2004-2024 17

2.3.2. Thyroid cancer incidence trends in females by type: number of new diagnoses, crude and age-standardised incidence rates, including average annual percentage change, 2004-2024 18

2.4. Thyroid cancer incidence trends: by age group 19

2.4.1. Thyroid cancer incidence trends in males, by age group: number of new diagnoses, crude and age-standardised incidence rates, including average annual percentage change, 2004-2024 19

2.4.2. Thyroid cancer incidence trends in females, by age group: number of new diagnoses, crude and age-standardised incidence rates, including average annual percentage change, 2004-2024 20

3. CANCER PREVALENCE 21

3.1. Thyroid cancer prevalence: by region 21

3.1.1. Thyroid cancer prevalence by region and sex: number of prevalent cases, crude and age-standardised prevalence rates on 31/12/2024 21

4. CANCER SURVIVAL 22

4.1. Thyroid cancer survival: by region 22
4.1.1. Thyroid cancer survival by region, sex and age group: number at risk and net survival probabilities, 2015-2024 22
4.2. Thyroid cancer survival: by tumour type and tumour stage 24
4.2.1. Thyroid cancer survival by type, clinical stage (cStage) and sex: number at risk and net survival probabilities, 2015-2024 24
4.2.2. Thyroid cancer survival by type, pathological stage (pStage) and sex: number at risk and net survival probabilities, 2015-2024 28
4.2.3. Thyroid cancer survival by type, stage and sex: number at risk and net survival probabilities, 2015-2024 32
5. CANCER SURVIVAL TRENDS 36
5.1. Thyroid cancer survival trends: by tumour type and tumour stage 36
5.1.1. Thyroid cancer survival trends by type, stage and sex: number at risk and net survival probabilities, 2004-2024 36
6. CANCER MORTALITY 43
6.1. Thyroid cancer mortality: by region 43
6.1.1. Thyroid cancer mortality* by region and sex: number of cancer deaths, age-specific, crude and age-standardised mortality rates, 2023 43
7. CANCER MORTALITY TRENDS 45
7.1. Thyroid cancer mortality trends: by region 45
7.1.1. Thyroid cancer mortality* trends in males, by region: number of cancer deaths, crude and age-standardised mortality rates, including average annual percentage change, 2004-2023 45
7.1.2. Thyroid cancer mortality* trends in females, by region: number of cancer deaths, crude and age-standardised mortality rates, including average annual percentage change, 2004-2023 46

1.1. Thyroid cancer incidence: by region

1.1.1. Thyroid cancer incidence by region and sex: number of new diagnoses, age-specific, crude and age-standardised incidence rates, 2024

	N [CR]																				ESR2013 (95%CI)
Region	**0-**	**5-**	**10-**	**15-**	**20-**	**25-**	**30-**	**35-**	**40-**	**45-**	**50-**	**55-**	**60-**	**65-**	**70-**	**75-**	**80-**	**85-**	**90-**	**95-**	**All ages**	
Males																						
Belgium	0	0	0	2	4	12	13	10	21	40	38	37	37	29	33	18	17	4	1	1	317	5.6
	[0.0]	[0.0]	[0.0]	[0.6]	[1.2]	[3.3]	[3.3]	[2.6]	[5.4]	[10.7]	[9.7]	[9.3]	[9.7]	[8.9]	[12.3]	[8.5]	[13.4]	[4.9]	[3.1]	[15.7]	[5.5]	(5.0; 6.2)
Brussels	0	0	0	1	2	2	3	1	3	7	4	1	4	1	2	1	1	0	0	1	34	6.2
	[0.0]	[0.0]	[0.0]	[2.6]	[4.9]	[3.9]	[5.6]	[2.1]	[6.6]	[15.9]	[9.7]	[2.8]	[13.5]	[4.6]	[11.8]	[7.8]	[12.2]	[0.0]	[0.0]	[177.6]	[5.6]	(4.0; 8.4)
Flanders	0	0	0	1	0	7	6	6	8	21	22	17	17	18	24	12	11	2	0	0	172	5.1
	[0.0]	[0.0]	[0.0]	[0.5]	[0.0]	[3.5]	[2.7]	[2.8]	[3.6]	[9.9]	[9.7]	[7.1]	[7.3]	[9.0]	[14.4]	[8.9]	[13.1]	[3.6]	[0.0]	[0.0]	[5.1]	(4.3; 5.9)
Wallonia	0	0	0	0	2	3	4	3	10	12	12	19	16	10	7	5	5	2	1	0	111	6.3
	[0.0]	[0.0]	[0.0]	[0.0]	[1.8]	[2.7]	[3.4]	[2.5]	[8.5]	[10.3]	[9.5]	[15.4]	[13.6]	[9.8]	[8.2]	[7.7]	[14.5]	[9.3]	[11.8]	[0.0]	[6.1]	(5.1; 7.5)
Females																						
Belgium	0	1	1	9	19	34	52	55	82	81	93	78	67	66	38	33	23	10	5	0	747	12.7
	[0.0]	[0.3]	[0.3]	[2.7]	[5.6]	[9.4]	[13.3]	[14.3]	[21.2]	[21.9]	[24.1]	[19.9]	[17.4]	[19.1]	[12.7]	[12.9]	[13.2]	[7.4]	[6.9]	[0.0]	[12.5]	(11.8; 13.6)
Brussels	0	0	0	1	2	4	8	7	10	11	14	7	7	4	5	3	1	2	0	0	86	14.6
	[0.0]	[0.0]	[0.0]	[2.7]	[4.6]	[7.1]	[14.7]	[14.4]	[22.0]	[26.3]	[36.3]	[20.3]	[22.9]	[15.9]	[23.2]	[16.2]	[7.8]	[20.7]	[0.0]	[0.0]	[13.5]	(11.5; 17.8)

Region	N [CR] 0-	5-	10-	15-	20-	25-	30-	35-	40-	45-	50-	55-	60-	65-	70-	75-	80-	85-	90-	95-	All ages	ESR2013 (95%CI)
Flanders	0	0	0	5	11	15	26	27	39	38	51	42	26	39	22	18	13	6	3	0	381	11.1
	[0.0]	[0.0]	[0.0]	[2.7]	[6.0]	[7.6]	[11.9]	[12.5]	[17.5]	[18.0]	[23.0]	[18.0]	[11.2]	[18.9]	[12.4]	[11.6]	[11.9]	[6.9]	[6.6]	[0.0]	[11.1]	(10.0; 12.3)
Wallonia	0	1	1	3	6	15	18	21	33	32	28	29	34	23	11	12	9	2	2	0	280	15.1
	[0.0]	[1.0]	[0.9]	[2.7]	[5.5]	[14.1]	[15.2]	[17.5]	[27.9]	[27.4]	[22.3]	[23.2]	[27.5]	[20.3]	[11.0]	[14.5]	[17.5]	[5.1]	[9.5]	[0.0]	[14.9]	(13.3; 16.8)

1.2. Thyroid cancer incidence: by tumour stage

1.2.1. Thyroid cancer incidence by clinical stage (cStage), sex and age group: number of new diagnoses, crude and age-standardised incidence rates, 2024

cStage	Males					Females				
	N[CR]				ESR2013 (95%CI)	N[CR]				ESR2013 (95%CI)
	15-54	55-74	75+	All ages 0+		15-54	55-74	75+	All ages 0+	
I	110 [3.7]	58 [4.2]	9 [2.0]	177 [3.1]	3.1 (2.7; 3.6)	332 [11.3]	130 [9.1]	27 [4.1]	490 [8.2]	8.5 (7.7; 9.2)
II	4 [0.1]	18 [1.3]	6 [1.3]	28 [0.5]	0.5 (0.3; 0.7)	2 [0.1]	21 [1.5]	11 [1.7]	35 [0.6]	0.6 (0.4; 0.7)
III	1 [0.0]	2 [0.1]	3 [0.7]	6 [0.1]	0.1 (0.0; 0.2)	0 [0.0]	4 [0.3]	4 [0.6]	8 [0.1]	0.1 (0.0; 0.2)
IV	0 [0.0]	14 [1.0]	13 [2.8]	27 [0.5]	0.5 (0.3; 0.7)	4 [0.1]	10 [0.7]	10 [1.5]	24 [0.4]	0.4 (0.2; 0.5)
X/NA	25 [0.8]	44 [3.2]	10 [2.2]	79 [1.4]	1.4 (1.1; 1.7)	87 [3.0]	84 [5.9]	19 [2.9]	190 [3.2]	3.2 (2.7; 3.6)

1.2.2. Thyroid cancer incidence by pathological stage (pStage), sex and age group: number of new diagnoses, crude and age-standardised incidence rates, 2024

pStage	Males					Females				
	N[CR]				ESR2013 (95%CI)	N[CR]				ESR2013 (95%CI)
	15-54	55-74	75+	All ages 0+		15-54	55-74	75+	All ages 0+	
I	130 [4.4]	82 [6.0]	11 [2.4]	223 [3.8]	3.9 (3.4; 4.4)	398 [13.5]	180 [12.7]	35 [5.3]	615 [10.3]	10.6 (9.8; 11.4)
II	0 [0.0]	27 [2.0]	11 [2.4]	38 [0.7]	0.7 (0.5; 0.9)	3 [0.1]	39 [2.7]	15 [2.3]	57 [1.0]	0.9 (0.7; 1.1)
III	1 [0.0]	2 [0.1]	2 [0.4]	5 [0.1]	0.1 (0.0; 0.2)	1 [0.0]	6 [0.4]	1 [0.2]	8 [0.1]	0.1 (0.0; 0.2)
IV	3 [0.1]	11 [0.8]	7 [1.5]	21 [0.4]	0.4 (0.2; 0.5)	7 [0.2]	9 [0.6]	5 [0.8]	21 [0.4]	0.3 (0.2; 0.5)
X/NA	6 [0.2]	14 [1.0]	10 [2.2]	30 [0.5]	0.6 (0.4; 0.8)	16 [0.5]	15 [1.1]	15 [2.3]	46 [0.8]	0.7 (0.5; 0.9)

1.2.3. Thyroid cancer incidence by stage, sex and age group: number of new diagnoses, crude and age-standardised incidence rates, 2024

Stage	Males					Females				
	N[CR]				ESR2013 (95%CI)	N[CR]				ESR2013 (95%CI)
	15-54	55-74	75+	All ages 0+		15-54	55-74	75+	All ages 0+	
I	133 [4.5]	82 [6.0]	12 [2.6]	227 [3.9]	4.0 (3.5; 4.5)	399 [13.5]	183 [12.9]	36 [5.5]	619 [10.4]	10.7 (9.8; 11.5)
II	1 [0.0]	27 [2.0]	11 [2.4]	39 [0.7]	0.7 (0.5; 0.9)	4 [0.1]	39 [2.7]	16 [2.4]	60 [1.0]	1.0 (0.7; 1.2)
III	1 [0.0]	2 [0.1]	2 [0.4]	5 [0.1]	0.1 (0.0; 0.2)	1 [0.0]	7 [0.5]	4 [0.6]	12 [0.2]	0.2 (0.1; 0.3)
IV	3 [0.1]	16 [1.2]	14 [3.0]	33 [0.6]	0.6 (0.4; 0.8)	7 [0.2]	11 [0.8]	10 [1.5]	28 [0.5]	0.4 (0.3; 0.6)
X/NA	2 [0.1]	9 [0.7]	2 [0.4]	13 [0.2]	0.2 (0.1; 0.3)	14 [0.5]	9 [0.6]	5 [0.8]	28 [0.5]	0.5 (0.3; 0.6)

1.3. Thyroid cancer incidence: by tumour type

1.3.1. Thyroid cancer incidence by type, sex and age group: number of new diagnoses, crude and age-standardised incidence rates, 2024

Type	Males					Females				
	N[CR]				ESR2013 (95%CI)	N[CR]				ESR2013 (95%CI)
	15-54	55-74	75+	All ages 0+		15-54	55-74	75+	All ages 0+	
Papillary carcinoma	121 [4.1]	89 [6.5]	21 [4.6]	231 [4.0]	4.1 (3.5; 4.6)	375 [12.7]	198 [13.9]	42 [6.4]	617 [10.3]	10.6 (9.7; 11.4)
Papillary carcinoma <55y	121 [4.1]	0 [0.0]	0 [0.0]	121 [2.1]	2.2 (1.8; 2.6)	375 [12.7]	0 [0.0]	0 [0.0]	377 [6.3]	6.8 (6.1; 7.4)
Papillary carcinoma 55+y	0 [0.0]	89 [6.5]	21 [4.6]	110 [1.9]	1.9 (1.5; 2.3)	0 [0.0]	198 [13.9]	42 [6.4]	240 [4.0]	3.8 (3.3; 4.3)
Follicular carcinoma	12 [0.4]	31 [2.3]	12 [2.6]	55 [0.9]	1.0 (0.7; 1.2)	37 [1.3]	32 [2.3]	16 [2.4]	85 [1.4]	1.4 (1.1; 1.7)
Follicular carcinoma <55y	12 [0.4]	0 [0.0]	0 [0.0]	12 [0.2]	0.2 (0.1; 0.3)	37 [1.3]	0 [0.0]	0 [0.0]	37 [0.6]	0.7 (0.4; 0.9)
Follicular carcinoma 55+y	0 [0.0]	31 [2.3]	12 [2.6]	43 [0.7]	0.8 (0.5; 1.0)	0 [0.0]	32 [2.3]	16 [2.4]	48 [0.8]	0.7 (0.5; 1.0)
Medullary carcinoma	4 [0.1]	7 [0.5]	2 [0.4]	13 [0.2]	0.2 (0.1; 0.4)	11 [0.4]	14 [1.0]	5 [0.8]	30 [0.5]	0.5 (0.3; 0.7)
Anaplastic carcinoma	0 [0.0]	7 [0.5]	4 [0.9]	11 [0.2]	0.2 (0.1; 0.3)	2 [0.1]	2 [0.1]	4 [0.6]	8 [0.1]	0.1 (0.0; 0.2)
Other	3 [0.1]	2 [0.1]	2 [0.4]	7 [0.1]	0.1 (0.0; 0.2)	0 [0.0]	3 [0.2]	4 [0.6]	7 [0.1]	0.1 (0.0; 0.2)

1.4. Thyroid cancer incidence: by tumour type and tumour stage

1.4.1. Thyroid cancer incidence by type, stage, sex and age group: number of new diagnoses, crude and age-standardised incidence rates, 2024

Type	Stage	Males					Females				
		N[CR]				ESR2013 (95%CI)	N[CR]				ESR2013 (95%CI)
		15-54	55-74	75+	All ages 0+		15-54	55-74	75+	All ages 0+	
Papillary carcinoma <55y	**I**	120 [4.0]	0 [0.0]	0 [0.0]	120 [2.1]	2.1 (1.8; 2.5)	370 [12.5]	0 [0.0]	0 [0.0]	371 [6.2]	6.7 (6.0; 7.3)
	II	1 [0.0]	0 [0.0]	0 [0.0]	1 [0.0]	0.0 (0.0; 0.1)	1 [0.0]	0 [0.0]	0 [0.0]	2 [0.0]	0.0 (0.0; 0.1)
	III	0 [0.0]	0 [0.0]	0 [0.0]	0 [0.0]	0.0 (0.0; 0.0)	0 [0.0]	0 [0.0]	0 [0.0]	0 [0.0]	0.0 (0.0; 0.0)
	IV	0 [0.0]	0 [0.0]	0 [0.0]	0 [0.0]	0.0 (0.0; 0.0)	0 [0.0]	0 [0.0]	0 [0.0]	0 [0.0]	0.0 (0.0; 0.0)
	X/NA	0 [0.0]	0 [0.0]	0 [0.0]	0 [0.0]	0.0 (0.0; 0.0)	4 [0.1]	0 [0.0]	0 [0.0]	4 [0.1]	0.1 (0.0; 0.1)
Papillary carcinoma 55+y	**I**	0 [0.0]	68 [5.0]	9 [2.0]	77 [1.3]	1.3 (1.0; 1.6)	0 [0.0]	161 [11.3]	26 [3.9]	187 [3.1]	3.0 (2.6; 3.4)
	II	0 [0.0]	16 [1.2]	6 [1.3]	22 [0.4]	0.4 (0.2; 0.5)	0 [0.0]	29 [2.0]	9 [1.4]	38 [0.6]	0.6 (0.4; 0.8)
	III	0 [0.0]	1 [0.1]	1 [0.2]	2 [0.0]	0.0 (0.0; 0.1)	0 [0.0]	1 [0.1]	4 [0.6]	5 [0.1]	0.1 (0.0; 0.1)
	IV	0 [0.0]	2 [0.1]	5 [1.1]	7 [0.1]	0.1 (0.0; 0.2)	0 [0.0]	4 [0.3]	1 [0.2]	5 [0.1]	0.1 (0.0; 0.2)
	X/NA	0 [0.0]	2 [0.1]	0 [0.0]	2 [0.0]	0.0 (0.0; 0.1)	0 [0.0]	3 [0.2]	2 [0.3]	5 [0.1]	0.1 (0.0; 0.1)
Follicular carcinoma <55y	**I**	10 [0.3]	0 [0.0]	0 [0.0]	10 [0.2]	0.2 (0.1; 0.3)	26 [0.9]	0 [0.0]	0 [0.0]	26 [0.4]	0.5 (0.3; 0.7)
	II	0 [0.0]	0 [0.0]	0 [0.0]	0 [0.0]	0.0 (0.0; 0.0)	1 [0.0]	0 [0.0]	0 [0.0]	1 [0.0]	0.0 (0.0; 0.1)
	III	0 [0.0]	0 [0.0]	0 [0.0]	0 [0.0]	0.0 (0.0; 0.0)	0 [0.0]	0 [0.0]	0 [0.0]	0 [0.0]	0.0 (0.0; 0.0)
	IV	0 [0.0]	0 [0.0]	0 [0.0]	0 [0.0]	0.0 (0.0; 0.0)	0 [0.0]	0 [0.0]	0 [0.0]	0 [0.0]	0.0 (0.0; 0.0)
	X/NA	2 [0.1]	0 [0.0]	0 [0.0]	2 [0.0]	0.0 (0.0; 0.1)	10 [0.3]	0 [0.0]	0 [0.0]	10 [0.2]	0.2 (0.1; 0.3)
Follicular carcinoma 55+y	**I**	0 [0.0]	11 [0.8]	1 [0.2]	12 [0.2]	0.2 (0.1; 0.3)	0 [0.0]	16 [1.1]	7 [1.1]	23 [0.4]	0.4 (0.2; 0.5)
	II	0 [0.0]	11 [0.8]	5 [1.1]	16 [0.3]	0.3 (0.1; 0.4)	0 [0.0]	8 [0.6]	5 [0.8]	13 [0.2]	0.2 (0.1; 0.3)
	III	0 [0.0]	1 [0.1]	1 [0.2]	2 [0.0]	0.0 (0.0; 0.1)	0 [0.0]	1 [0.1]	0 [0.0]	1 [0.0]	0.0 (0.0; 0.0)
	IV	0 [0.0]	4 [0.3]	3 [0.7]	7 [0.1]	0.1 (0.0; 0.2)	0 [0.0]	3 [0.2]	1 [0.2]	4 [0.1]	0.1 (0.0; 0.1)

Type	Stage	Males					Females				
		N[CR]				ESR2013 (95%CI)	N[CR]				ESR2013 (95%CI)
		15-54	55-74	75+	All ages 0+		15-54	55-74	75+	All ages 0+	
	X/NA	0 [0.0]	4 [0.3]	2 [0.4]	6 [0.1]	0.1 (0.0; 0.2)	0 [0.0]	4 [0.3]	3 [0.5]	7 [0.1]	0.1 (0.0; 0.2)
Medullary carcinoma	I	1 [0.0]	3 [0.2]	2 [0.4]	6 [0.1]	0.1 (0.0; 0.2)	3 [0.1]	6 [0.4]	3 [0.5]	12 [0.2]	0.2 (0.1; 0.3)
	II	0 [0.0]	0 [0.0]	0 [0.0]	0 [0.0]	0.0 (0.0; 0.0)	2 [0.1]	1 [0.1]	0 [0.0]	3 [0.1]	0.1 (0.0; 0.1)
	III	1 [0.0]	0 [0.0]	0 [0.0]	1 [0.0]	0.0 (0.0; 0.1)	1 [0.0]	5 [0.4]	0 [0.0]	6 [0.1]	0.1 (0.0; 0.2)
	IV	2 [0.1]	3 [0.2]	0 [0.0]	5 [0.1]	0.1 (0.0; 0.2)	5 [0.2]	2 [0.1]	2 [0.3]	9 [0.2]	0.2 (0.1; 0.3)
	X/NA	0 [0.0]	1 [0.1]	0 [0.0]	1 [0.0]	0.0 (0.0; 0.1)	0 [0.0]	0 [0.0]	0 [0.0]	0 [0.0]	0.0 (0.0; 0.0)
Anaplastic carcinoma	IV	0 [0.0]	7 [0.5]	4 [0.9]	11 [0.2]	0.2 (0.1; 0.3)	2 [0.1]	2 [0.1]	4 [0.6]	8 [0.1]	0.1 (0.0; 0.2)
	X/NA	0 [0.0]	0 [0.0]	0 [0.0]	0 [0.0]	0.0 (0.0; 0.0)	0 [0.0]	0 [0.0]	0 [0.0]	0 [0.0]	0.0 (0.0; 0.0)
Other	I	2 [0.1]	0 [0.0]	0 [0.0]	2 [0.0]	0.0 (0.0; 0.1)	0 [0.0]	0 [0.0]	0 [0.0]	0 [0.0]	0.0 (0.0; 0.0)
	II	0 [0.0]	0 [0.0]	0 [0.0]	0 [0.0]	0.0 (0.0; 0.0)	0 [0.0]	1 [0.1]	2 [0.3]	3 [0.1]	0.0 (0.0; 0.1)
	III	0 [0.0]	0 [0.0]	0 [0.0]	0 [0.0]	0.0 (0.0; 0.0)	0 [0.0]	0 [0.0]	0 [0.0]	0 [0.0]	0.0 (0.0; 0.0)
	IV	1 [0.0]	0 [0.0]	2 [0.4]	3 [0.1]	0.1 (0.0; 0.1)	0 [0.0]	0 [0.0]	2 [0.3]	2 [0.0]	0.0 (0.0; 0.1)
	X/NA	0 [0.0]	2 [0.1]	0 [0.0]	2 [0.0]	0.0 (0.0; 0.1)	0 [0.0]	2 [0.1]	0 [0.0]	2 [0.0]	0.0 (0.0; 0.1)

2.1. Thyroid cancer incidence trends: by region

2.1.1. Thyroid cancer incidence trends in males, by region: number of new diagnoses, crude and age-standardised incidence rates, including average annual percentage change, 2004-2024

Region		2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	AAPC, % (95%CI)	Period
Belgium	**N**	157	169	177	189	213	258	204	241	250	253	268	282	266	291	254	262	230	309	300	305	317		
	CR	3.1	3.3	3.4	3.6	4.1	4.9	3.8	4.5	4.6	4.6	4.9	5.1	4.8	5.2	4.5	4.7	4.1	5.4	5.3	5.3	5.5		
	ESR2013	3.3	3.6	3.7	3.8	4.4	5.2	4.0	4.8	4.8	5.0	5.2	5.3	5.0	5.4	4.7	4.9	4.3	5.6	5.4	5.4	5.6	2.2 (1.5; 2.8)	2004-2024
																							4.8 (2.9; 6.7)	2004-2012
																							0.5 (-0.6; 1.7)	2013-2024
Brussels	**N**	23	17	21	25	33	28	29	27	35	37	42	35	31	36	35	32	19	35	22	35	34		
	CR	4.8	3.5	4.3	5.0	6.5	5.4	5.5	5.0	6.3	6.6	7.4	6.1	5.3	6.2	6.0	5.4	3.2	5.8	3.7	5.8	5.6		
	ESR2013	5.9	3.8	5.2	5.8	7.5	6.7	6.5	6.5	7.9	8.2	8.6	8.1	6.8	8.0	7.4	6.2	4.1	7.8	4.5	6.4	6.2	0.6 (-0.7; 2.0)	2004-2024
																							6.2 (2.6; 9.9)	2004-2013
																							-3.7 (-6.3; -1.0)	2014-2024
Flanders	**N**	64	69	79	77	91	109	91	133	116	112	119	125	127	151	129	134	131	168	156	174	172		
	CR	2.2	2.3	2.6	2.6	3.0	3.6	2.9	4.3	3.7	3.6	3.8	3.9	4.0	4.7	4.0	4.1	4.0	5.1	4.7	5.2	5.1		
	ESR2013	2.4	2.5	2.7	2.6	3.1	3.7	3.0	4.5	3.8	3.7	4.0	3.9	4.0	4.7	4.0	4.2	4.0	5.2	4.7	5.1	5.1	3.9 (3.1; 4.7)	2004-2024
																							7.5 (4.5; 10.5)	2004-2010
																							2.4 (1.3; 3.5)	2011-2024

Region		2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	AAPC, % (95%CI)	Period
Wallonia	**N**	70	83	77	87	89	121	84	81	99	104	107	122	108	104	90	96	80	106	122	96	111		
	CR	4.3	5.0	4.6	5.2	5.3	7.2	4.9	4.7	5.7	6.0	6.1	7.0	6.1	5.9	5.1	5.4	4.5	5.9	6.8	5.3	6.1		
	ESR2013	4.5	5.6	5.0	5.6	5.9	7.6	5.3	4.9	6.1	6.4	6.6	7.3	6.5	6.3	5.3	5.8	4.6	6.1	7.0	5.5	6.3	0.6 (-0.4; 1.7)	2004-2024

Note: In case a change in trend is detected, an estimated APC per time segment is given as well as Average Annual Percentage Change (AAPC) for the entire incidence period.

2.1.2. Thyroid cancer incidence trends in females, by region: number of new diagnoses, crude and age-standardised incidence rates, including average annual percentage change, 2004-2024

Region		2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	AAPC, % (95%CI)	Period
Belgium	**N**	473	502	510	513	547	635	652	671	707	694	806	746	777	754	722	707	590	761	730	726	747		
	CR	8.9	9.4	9.5	9.5	10.1	11.6	11.8	12.0	12.6	12.3	14.2	13.1	13.6	13.1	12.5	12.2	10.1	13.0	12.4	12.2	12.5		
	ESR2013	9.1	9.5	9.7	9.6	10.3	11.8	12.0	12.3	12.8	12.5	14.4	13.3	13.8	13.4	12.7	12.4	10.3	13.1	12.6	12.5	12.7	1.6 (1.1; 2.1)	2004-2024
																							4.7 (3.4; 6.0)	2004-2013
																							-0.9 (-1.9; 0.0)	2014-2024
Brussels	**N**	77	54	63	87	64	98	88	104	133	109	135	108	112	109	105	86	77	81	94	96	86		
	CR	14.8	10.3	11.9	16.3	11.8	17.7	15.6	18.0	22.7	18.4	22.6	17.9	18.4	17.9	17.2	14.0	12.4	13.0	15.1	15.2	13.5		
	ESR2013	16.5	11.4	12.5	17.7	12.9	19.7	17.1	20.1	24.2	20.6	26.0	19.6	20.1	19.3	18.9	15.5	13.2	14.2	16.8	16.5	14.6	0.7 (-0.4; 1.8)	2004-2024
																							7.6 (4.2; 11.1)	2004-2012
																							-3.7 (-5.6; -1.7)	2013-2024
Flanders	**N**	166	228	218	206	222	261	285	325	319	303	379	369	380	343	346	368	308	398	368	346	381		
	CR	5.4	7.4	7.1	6.6	7.1	8.3	9.0	10.2	9.9	9.4	11.7	11.3	11.6	10.4	10.4	11.1	9.2	11.8	10.9	10.1	11.1		
	ESR2013	5.5	7.4	7.1	6.6	7.1	8.3	8.9	10.2	9.9	9.3	11.6	11.4	11.8	10.4	10.4	11.1	9.2	11.8	10.9	10.1	11.1	2.9 (2.2; 3.5)	2004-2024
																							6.4 (4.9; 7.8)	2004-2014
																							-0.5 (-1.9; 0.8)	2015-2024
Wallonia	**N**	230	220	229	220	261	276	279	242	255	282	292	269	285	302	271	253	205	282	268	284	280		
	CR	13.2	12.6	13.0	12.4	14.7	15.4	15.5	13.4	14.0	15.4	15.9	14.6	15.4	16.3	14.6	13.6	11.0	15.1	14.3	15.1	14.9		
	ESR2013	13.6	13.0	13.4	12.9	15.2	16.1	16.0	13.9	14.4	15.8	16.5	15.0	15.9	16.9	14.9	13.9	11.3	15.4	14.6	15.4	15.1	0.4 (-0.3; 1.1)	2004-2024
																							2.1 (0.1; 4.1)	2004-2012
																							-0.7 (-1.9; 0.6)	2013-2024

Note: In case a change in trend is detected, an estimated APC per time segment is given as well as Average Annual Percentage Change (AAPC) for the entire incidence period.

2.2. Thyroid cancer incidence trends: by tumour stage

2.2.1. Thyroid cancer incidence trends by stage and sex: number of new diagnoses, crude and age-standardised incidence rates, 2020-2024, including average annual percentage change from 2004 onwards

Stage		Males							Females						
		2020	2021	2022	2023	2024	AAPC, % (95%CI)	Period	2020	2021	2022	2023	2024	AAPC, % (95%CI)	Period
I	N	148	212	212	218	227			492	657	603	618	619		
	CR	2.6	3.7	3.7	3.8	3.9			8.4	11.2	10.3	10.4	10.4		
	ESR2013	2.7	3.8	3.8	3.9	4.0	8.0 (6.7; 9.2)	2004-2024	8.7	11.5	10.6	10.7	10.7	6.4 (5.6; 7.2)	2004-2024
							13.2 (10.0; 16.6)	2004-2013						14.7 (11.9; 17.6)	2004-2011
							3.8 (1.5; 6.2)	2014-2024						4.4 (0.7; 8.3)	2012-2015
														1.1 (-0.6; 3.0)	2016-2024
II	N	44	54	42	44	39			45	50	56	51	60		
	CR	0.8	1.0	0.7	0.8	0.7			0.8	0.9	1.0	0.9	1.0		
	ESR2013	0.8	1.0	0.8	0.8	0.7	7.3 (5.1; 9.5)	2004-2024	0.7	0.8	0.9	0.8	1.0	1.9 (0.8; 3.0)	2004-2024
														7.4 (5.2; 9.7)	2004-2015
														-4.5 (-7.0; -2.0)	2016-2024
III	N	5	7	6	3	5			8	5	10	7	12		
	CR	0.1	0.1	0.1	0.1	0.1			0.1	0.1	0.2	0.1	0.2		
	ESR2013	0.1	0.1	0.1	0.1	0.1	-9.5 (-13.3; -5.6)	2004-2024	0.1	0.1	0.1	0.1	0.2	-8.0 (-12.4; -3.3)	2004-2024
							9.6 (-2.5; 23.2)	2004-2012						11.6 (-0.5; 25.3)	2004-2013
							-19.8 (-34.6; -1.5)	2013-2016						-41.1 (-53.5; -25.4)	2014-2017
							-20.7 (-29.4; -10.9)	2017-2024						-7.3 (-21.0; 8.7)	2018-2024
IV	N	25	26	29	33	33			29	36	39	30	28		
	CR	0.4	0.5	0.5	0.6	0.6			0.5	0.6	0.7	0.5	0.5		
	ESR2013	0.5	0.5	0.5	0.6	0.6	-0.9 (-2.7; 1.0)	2004-2024	0.4	0.6	0.6	0.5	0.4	-2.4 (-3.7; -1.0)	2004-2024

Stage		Males							Females						
		2020	2021	2022	2023	2024	AAPC, % (95%CI)	Period	2020	2021	2022	2023	2024	AAPC, % (95%CI)	Period
							5.1 (-1.1; 11.5)	2004-2011						3.4 (-1.8; 8.9)	2004-2010
							-7.7 (-15.5; 0.9)	2012-2015						-4.8 (-6.6; -2.9)	2011-2024
							-2.2 (-6.4; 2.1)	2016-2024							
X/NA	**N**	8	10	11	7	13			16	13	22	20	28		
	CR	0.1	0.2	0.2	0.1	0.2			0.3	0.2	0.4	0.3	0.5		
	ESR2013	0.2	0.2	0.2	0.1	0.2	-11.1 (-12.5; -9.8)	2004-2024	0.3	0.2	0.4	0.3	0.5	-11.0 (-13.0; -9.0)	2004-2024
														-14.5 (-16.1; -12.9)	2004-2022
														27.8 (1.5; 61.1)	2023-2024

Note: In case a change in trend is detected, an estimated APC per time segment is given as well as Average Annual Percentage Change (AAPC) for the entire incidence period.

2.3. Thyroid cancer incidence trends: by tumour type

2.3.1. Thyroid cancer incidence trends in males by type: number of new diagnoses, crude and age-standardised incidence rates, including average annual percentage change, 2004-2024

Type		2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	AAPC, %	(95%CI)	Period
Papillary carcinoma	**N**	101	113	119	127	130	182	139	169	188	187	199	222	193	221	191	194	157	230	203	216	231			
	CR	2.0	2.2	2.3	2.5	2.5	3.5	2.6	3.1	3.5	3.4	3.6	4.0	3.5	4.0	3.4	3.4	2.8	4.1	3.6	3.7	4.0			
	ESR2013	2.1	2.4	2.4	2.5	2.6	3.6	2.7	3.3	3.6	3.6	3.8	4.1	3.6	4.1	3.5	3.6	2.9	4.1	3.6	3.8	4.1	2.8	(2.0; 3.6)	2004-2024
																							6.4	(4.3; 8.5)	2004-2013
																							0.0	(-1.6; 1.5)	2014-2024
Follicular carcinoma	**N**	29	27	35	36	38	38	30	35	32	33	43	37	41	43	32	45	39	47	58	49	55			
	CR	0.6	0.5	0.7	0.7	0.7	0.7	0.6	0.7	0.6	0.6	0.8	0.7	0.7	0.8	0.6	0.8	0.7	0.8	1.0	0.9	0.9			
	ESR2013	0.7	0.5	0.8	0.7	0.8	0.8	0.6	0.7	0.6	0.7	0.9	0.7	0.8	0.8	0.6	0.8	0.7	0.9	1.0	0.9	1.0	1.6	(0.6; 2.7)	2004-2024
Medullary carcinoma	**N**	9	16	17	15	21	18	18	19	19	11	11	15	13	14	13	15	16	15	13	23	13			
	CR	0.2	0.3	0.3	0.3	0.4	0.3	0.3	0.4	0.4	0.2	0.2	0.3	0.2	0.3	0.2	0.3	0.3	0.3	0.2	0.4	0.2			
	ESR2013	0.2	0.4	0.4	0.3	0.4	0.4	0.4	0.4	0.4	0.2	0.2	0.3	0.3	0.3	0.2	0.3	0.3	0.3	0.2	0.4	0.2	-0.8	(-3.0; 1.4)	2004-2024
																							-1.4	(-3.5; 0.8)	2004-2021
																							2.6	(-12.6; 20.5)	2022-2024
Anaplastic carcinoma	**N**	7	10	3	10	18	17	10	8	8	14	8	7	11	11	10	4	11	14	13	11	11			
	CR	0.1	0.2	0.1	0.2	0.3	0.3	0.2	0.1	0.1	0.3	0.1	0.1	0.2	0.2	0.2	0.1	0.2	0.2	0.2	0.2	0.2			
	ESR2013	0.2	0.2	0.1	0.2	0.4	0.4	0.2	0.2	0.2	0.3	0.2	0.1	0.2	0.2	0.2	0.1	0.2	0.3	0.2	0.2	0.2	0.1	(-3.1; 3.3)	2004-2024
Other	**N**	11	3	3	1	6	3	7	10	3	8	7	1	8	2	8	4	7	3	13	6	7			
	CR	0.2	0.1	0.1	0.0	0.1	0.1	0.1	0.2	0.1	0.1	0.1	0.0	0.1	0.0	0.1	0.1	0.1	0.1	0.2	0.1	0.1			
	ESR2013	0.2	0.1	0.1	0.0	0.1	0.1	0.1	0.2	0.1	0.2	0.1	0.0	0.2	0.0	0.2	0.1	0.1	0.1	0.3	0.1	0.1	1.6	(-3.8; 7.3)	2004-2024

Note: In case a change in trend is detected, an estimated APC per time segment is given as well as Average Annual Percentage Change (AAPC) for the entire incidence period.

2.3.2. Thyroid cancer incidence trends in females by type: number of new diagnoses, crude and age-standardised incidence rates, including average annual percentage change, 2004-2024

Type		2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	AAPC, %	(95%CI)	Period
Papillary carcinoma	**N**	347	381	426	391	438	499	517	558	591	566	684	631	652	609	607	575	477	640	589	585	617			
	CR	6.5	7.1	7.9	7.2	8.0	9.1	9.4	10.0	10.5	10.0	12.1	11.1	11.4	10.6	10.5	9.9	8.2	11.0	10.0	9.9	10.3			
	ESR2013	6.6	7.2	8.1	7.4	8.2	9.3	9.5	10.2	10.7	10.2	12.3	11.3	11.6	10.9	10.7	10.1	8.4	11.1	10.3	10.1	10.6	2.0	(1.4; 2.5)	2004-2024
																							5.9	(4.5; 7.4)	2004-2013
																							-1.1	(-2.2; 0.0)	2014-2024
Follicular carcinoma	**N**	80	65	51	76	71	83	83	63	70	81	80	83	74	96	66	80	70	66	91	90	85			
	CR	1.5	1.2	1.0	1.4	1.3	1.5	1.5	1.1	1.2	1.4	1.4	1.5	1.3	1.7	1.1	1.4	1.2	1.1	1.5	1.5	1.4			
	ESR2013	1.5	1.3	1.0	1.4	1.4	1.5	1.5	1.1	1.2	1.5	1.4	1.5	1.3	1.7	1.1	1.4	1.2	1.1	1.5	1.5	1.4	0.2	(-0.8; 1.3)	2004-2024
Medullary carcinoma	**N**	24	22	16	18	22	21	23	26	19	18	23	9	20	18	20	20	22	27	22	24	30			
	CR	0.5	0.4	0.3	0.3	0.4	0.4	0.4	0.5	0.3	0.3	0.4	0.2	0.3	0.3	0.3	0.3	0.4	0.5	0.4	0.4	0.5			
	ESR2013	0.5	0.4	0.3	0.3	0.4	0.4	0.4	0.5	0.3	0.3	0.4	0.2	0.3	0.3	0.3	0.3	0.4	0.5	0.4	0.4	0.5	1.0	(-1.2; 3.2)	2004-2024
																							-1.4	(-3.8; 1.0)	2004-2020
																							11.1	(-1.4; 25.1)	2021-2024
Anaplastic carcinoma	**N**	14	21	10	17	12	21	15	16	17	16	8	13	11	11	14	17	11	15	16	14	8			
	CR	0.3	0.4	0.2	0.3	0.2	0.4	0.3	0.3	0.3	0.3	0.1	0.2	0.2	0.2	0.2	0.3	0.2	0.3	0.3	0.2	0.1			
	ESR2013	0.3	0.4	0.2	0.3	0.2	0.4	0.3	0.3	0.3	0.3	0.1	0.2	0.2	0.2	0.2	0.2	0.1	0.2	0.2	0.2	0.1	-2.6	(-4.7; -0.5)	2004-2024
Other	**N**	8	13	7	11	4	11	14	8	10	13	11	10	20	20	15	15	10	13	12	13	7			
	CR	0.2	0.2	0.1	0.2	0.1	0.2	0.3	0.1	0.2	0.2	0.2	0.2	0.3	0.3	0.3	0.3	0.2	0.2	0.2	0.2	0.1			
	ESR2013	0.1	0.2	0.1	0.2	0.1	0.2	0.3	0.1	0.2	0.2	0.2	0.2	0.3	0.3	0.3	0.3	0.2	0.2	0.2	0.2	0.1	-0.7	(-3.4; 2.1)	2004-2024
																							3.6	(0.4; 6.8)	2004-2020
																							-16.1	(-28.0; -2.2)	2021-2024

Note: In case a change in trend is detected, an estimated APC per time segment is given as well as Average Annual Percentage Change (AAPC) for the entire incidence period.

2.4. Thyroid cancer incidence trends: by age group

2.4.1. Thyroid cancer incidence trends in males, by age group: number of new diagnoses, crude and age-standardised incidence rates, including average annual percentage change, 2004-2024

Age		2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	AAPC, % (95%CI)	Period
15-54	**N**	76	89	89	104	99	119	100	108	132	103	128	139	109	129	101	114	96	123	105	132	140		
	CR	2.6	3.1	3.1	3.6	3.4	4.1	3.4	3.7	4.5	3.5	4.3	4.7	3.7	4.4	3.4	3.9	3.3	4.2	3.6	4.4	4.7		
	ESR2013	2.6	3.1	3.1	3.6	3.4	4.1	3.4	3.7	4.5	3.5	4.3	4.7	3.7	4.4	3.4	3.9	3.3	4.3	3.6	4.6	4.8	2.0 (0.9; 3.1)	2004-2024
																							4.8 (1.7; 7.9)	2004-2012
																							-2.1 (-7.0; 3.0)	2013-2016
																							1.3 (-1.6; 4.3)	2017-2024
55-74	**N**	67	66	74	68	82	108	81	99	94	120	117	116	127	128	124	115	98	143	151	136	136		
	CR	6.7	6.5	7.2	6.6	7.8	10.1	7.5	9.0	8.4	10.5	10.1	9.8	10.5	10.3	9.8	8.9	7.4	10.7	11.2	10.0	9.9		
	ESR2013	6.7	6.5	7.2	6.4	7.9	10.2	7.5	9.1	8.5	10.7	10.3	9.7	10.6	10.4	9.8	9.1	7.6	10.8	11.2	9.9	10.0	2.2 (1.4; 3.1)	2004-2024
																							5.0 (2.8; 7.3)	2004-2013
																							0.0 (-1.7; 1.7)	2014-2024
75+	**N**	14	14	13	15	30	31	21	34	24	29	22	27	30	33	27	30	36	41	43	37	41		
	CR	4.8	4.6	4.1	4.6	8.9	9.0	5.9	9.4	6.5	7.7	5.7	6.9	7.6	8.4	6.8	7.4	8.7	9.9	10.0	8.3	8.9		
	ESR2013	4.8	4.9	4.0	4.7	8.2	8.1	5.3	8.6	6.0	7.4	6.4	6.5	7.5	7.9	6.7	7.7	8.9	9.9	9.9	8.1	8.9	3.2 (1.9; 4.6)	2004-2024

Note: In case a change in trend is detected, an estimated APC per time segment is given as well as Average Annual Percentage Change (AAPC) for the entire incidence period.

2.4.2. Thyroid cancer incidence trends in females, by age group: number of new diagnoses, crude and age-standardised incidence rates, including average annual percentage change, 2004-2024

Age		2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	AAPC, % (95%CI)	Period
15-54	**N**	284	297	321	319	317	369	363	411	426	386	476	425	455	427	394	382	350	421	414	407	425		
	CR	10.1	10.5	11.3	11.2	11.1	12.8	12.6	14.1	14.6	13.2	16.4	14.6	15.7	14.7	13.6	13.2	12.1	14.6	14.3	13.9	14.4		
	ESR2013	10.1	10.5	11.4	11.2	11.1	12.9	12.6	14.2	14.7	13.3	16.4	14.7	15.8	14.9	13.7	13.3	12.3	14.7	14.5	14.1	14.7	1.6 (0.9; 2.2)	2004-2024
																							4.3 (1.3; 7.3)	2004-2014
																							-0.6 (-5.7; 4.8)	2015-2009
																							-0.9 (-2.1; 0.3)	2010-2024
55-74	**N**	146	152	147	156	186	209	217	200	211	238	262	265	251	256	263	259	184	265	243	245	249		
	CR	13.3	13.8	13.2	14.0	16.5	18.3	18.8	17.0	17.7	19.6	21.3	21.2	19.7	19.6	19.8	19.1	13.4	19.0	17.3	17.3	17.5		
	ESR2013	13.3	13.8	13.2	14.0	16.4	18.3	18.7	17.1	17.7	19.4	21.1	21.0	19.7	19.6	19.8	19.1	13.4	19.0	17.3	17.3	17.5	1.2 (0.5; 1.9)	2004-2024
																							4.7 (3.2; 6.3)	2004-2014
																							-2.2 (-3.7; -0.8)	2015-2024
75+	**N**	41	52	38	35	43	54	68	57	67	63	64	54	69	70	60	64	53	72	70	68	71		
	CR	7.9	9.8	7.0	6.3	7.5	9.3	11.6	9.6	11.2	10.4	10.5	8.8	11.2	11.4	9.8	10.4	8.5	11.6	11.0	10.5	10.8		
	ESR2013	7.9	9.6	7.2	6.3	7.7	9.2	11.3	9.7	11.6	10.9	10.7	9.0	11.5	12.6	10.4	11.3	8.8	12.2	11.6	11.3	11.2	2.0 (0.9; 3.2)	2004-2024

Note: In case a change in trend is detected, an estimated APC per time segment is given as well as Average Annual Percentage Change (AAPC) for the entire incidence period.

3.1. Thyroid cancer prevalence: by region

3.1.1. Thyroid cancer prevalence by region and sex: number of prevalent cases, crude and age-standardised prevalence rates on 31/12/2024

Region		Males					Females				
		1-year	5-year	10-year	15-year	20-year	1-year	5-year	10-year	15-year	20-year
Belgium	**N**	299	1,301	2,352	3,166	3,754	732	3,369	6,598	9,458	11,457
	CR	5.1	22.3	40.3	54	64	12.2	56.2	110.0	158	191
	ESR2013	5.2	22.7	41.1	55.4	65.7	12.4	56.9	110.8	157.9	190.2
Brussels	**N**	32	130	263	382	454	84	418	850	1,309	1,570
	CR	5.2	21.1	42.7	62.1	73.8	13.1	65.3	132.7	204.4	245.1
	ESR2013	5.6	25.3	53.7	79.2	95.5	14.3	72.7	149.9	235.0	285.1
Flanders	**N**	159	698	1,207	1,560	1,784	373	1,691	3,261	4,529	5,336
	CR	4.7	20.5	35.5	45.9	52.5	10.8	48.8	94.1	130.7	154.0
	ESR2013	4.7	20.3	35.1	45.4	51.9	10.8	48.9	93.6	129.0	151.0
Wallonia	**N**	108	473	882	1,224	1,516	275	1,260	2,487	3,620	4,551
	CR	6.0	26.1	48.6	67.4	83.5	14.5	66.7	131.6	191.5	240.8
	ESR2013	6.1	26.5	49.8	69.2	85.9	14.8	67.5	131.9	190.5	237.3

4.1. Thyroid cancer survival: by region

4.1.1. Thyroid cancer survival by region, sex and age group: number at risk and net survival probabilities, 2015-2024

			Net Survival Probability, 2015-2024			
Region	**Age**	**N at risk**	**1-y (95%CI)**	**3-y (95%CI)**	**5-y (95%CI)**	**10-y (95%CI)**
Total	**All ages 15+**	9,991	96.7% (96.3%; 97.1%)	95.8% (95.3%; 96.4%)	95.2% (94.5%; 95.9%)	94.7% (92.1%; 97.3%)
Males						
Belgium	**All ages 15+**	2,787	95.4% (94.5%; 96.3%)	93.2% (91.9%; 94.5%)	92.2% (90.5%; 93.9%)	88.4% (81.6%; 95.9%)
	15-54	1,180	99.4% (98.8%; 99.9%)	98.9% (98.1%; 99.7%)	97.7% (96.5%; 98.9%)	97.5% (95.6%; 99.4%)
	55-74	1,263	95.9% (94.6%; 97.2%)	93.2% (91.4%; 95.1%)	91.8% (89.4%; 94.3%)	85.9% (80.8%; 91.3%)
	75+	344	79.9% (75.1%; 85.0%)	73.3% (66.9%; 80.4%)	74.1% (65.4%; 83.9%)	68.8% (37.7%; 125.5%)
Brussels	**All ages 15+**	311	96.4% (94.1%; 98.8%)	95.6% (92.1%; 99.2%)	94.0% (89.4%; 98.8%)	102.0% (95.8%; 108.6%)
	15-54	152	100.0% (100.0%; 100.0%)	100.0% (98.7%; 101.3%)	99.5% (97.0%; 102.1%)	100.6% (97.0%; 104.3%)
	55-74	135	94.5% (90.3%; 98.8%)	94.6% (89.2%; 100.3%)	94.0% (87.1%; 101.4%)	102.1% (91.4%; 114.1%)
	75+	24	N<50	N<50	N<50	N<50
Flanders	**All ages 15+**	1,446	94.2% (92.8%; 95.5%)	91.3% (89.5%; 93.3%)	90.2% (87.7%; 92.7%)	84.3% (71.9%; 98.9%)
	15-54	582	99.0% (98.1%; 99.9%)	97.9% (96.6%; 99.2%)	96.3% (94.4%; 98.3%)	96.5% (93.8%; 99.2%)
	55-74	641	94.8% (92.9%; 96.7%)	91.2% (88.5%; 94.0%)	89.3% (85.9%; 92.8%)	79.7% (72.7%; 87.4%)
	75+	223	79.8% (73.9%; 86.1%)	74.5% (66.8%; 83.2%)	76.2% (65.3%; 88.8%)	74.1% (35.4%; 154.8%)
Wallonia	**All ages 15+**	1,030	96.7% (95.4%; 98.0%)	95.0% (93.0%; 97.0%)	94.4% (91.9%; 97.0%)	89.9% (84.6%; 95.6%)

Net Survival Probability, 2015-2024						
Region	**Age**	**N at risk**	**1-y (95%CI)**	**3-y (95%CI)**	**5-y (95%CI)**	**10-y (95%CI)**
	15-54	446	99.6% (98.8%; 100.3%)	99.8% (98.8%; 100.8%)	99.0% (97.3%; 100.7%)	97.9% (94.8%; 101.1%)
	55-74	487	97.6% (95.9%; 99.5%)	95.4% (92.5%; 98.3%)	94.4% (90.5%; 98.5%)	88.6% (80.1%; 98.1%)
	75+	97	76.9% (68.3%; 86.7%)	69.3% (57.5%; 83.4%)	71.6% (57.3%; 89.6%)	52.6% (27.1%; 102.2%)
Females						
Belgium	**All ages 15+**	7,204	97.2% (96.8%; 97.7%)	96.8% (96.3%; 97.4%)	96.3% (95.6%; 97.1%)	97.0% (94.9%; 99.2%)
	15-54	4,088	99.7% (99.5%; 99.9%)	99.6% (99.4%; 99.9%)	99.5% (99.1%; 99.8%)	99.6% (98.9%; 100.2%)
	55-74	2,467	97.4% (96.7%; 98.1%)	96.8% (95.8%; 97.8%)	95.9% (94.6%; 97.2%)	96.3% (93.8%; 98.9%)
	75+	649	80.5% (77.1%; 84.0%)	79.2% (74.8%; 83.8%)	78.1% (72.0%; 84.8%)	83.5% (64.7%; 107.8%)
Brussels	**All ages 15+**	942	99.0% (98.2%; 99.9%)	99.1% (97.8%; 100.4%)	96.7% (94.3%; 99.3%)	94.3% (89.0%; 100.0%)
	15-54	581	99.9% (99.6%; 100.3%)	99.8% (99.2%; 100.4%)	99.3% (98.3%; 100.4%)	99.3% (97.5%; 101.2%)
	55-74	297	98.7% (97.1%; 100.4%)	98.8% (96.4%; 101.2%)	94.9% (90.8%; 99.2%)	89.8% (80.7%; 99.9%)
	75+	64	91.6% (83.0%; 101.0%)	93.2% (80.1%; 108.4%)	82.1% (60.2%; 112.1%)	72.1% (38.5%; 135.0%)
Flanders	**All ages 15+**	3,576	96.0% (95.3%; 96.7%)	95.4% (94.5%; 96.3%)	95.0% (93.8%; 96.1%)	97.3% (95.1%; 99.4%)
	15-54	1,959	99.8% (99.6%; 100.0%)	99.6% (99.2%; 100.0%)	99.3% (98.8%; 99.9%)	99.2% (98.4%; 100.1%)
	55-74	1,222	96.0% (94.8%; 97.2%)	95.0% (93.5%; 96.6%)	94.6% (92.7%; 96.5%)	95.7% (92.7%; 98.9%)
	75+	395	77.3% (72.9%; 82.1%)	75.5% (70.0%; 81.5%)	74.5% (67.2%; 82.6%)	90.9% (73.0%; 113.4%)
Wallonia	**All ages 15+**	2,686	98.1% (97.5%; 98.8%)	97.9% (97.1%; 98.8%)	98.0% (96.9%; 99.1%)	97.6% (93.0%; 102.3%)
	15-54	1,548	99.6% (99.2%; 99.9%)	99.6% (99.2%; 100.1%)	99.7% (99.1%; 100.3%)	100.0% (99.0%; 101.1%)
	55-74	948	98.7% (97.8%; 99.6%)	98.4% (97.0%; 99.9%)	97.9% (95.9%; 99.9%)	99.1% (95.0%; 103.3%)
	75+	190	83.2% (77.3%; 89.6%)	81.1% (73.5%; 89.6%)	83.5% (73.2%; 95.3%)	70.3% (36.5%; 135.5%)

Note: Survival results obtained on very small groups are considered to be too uncertain, therefore a minimum size threshold of 50 is applied in the reporting of the Net Survival estimation.

4.2. Thyroid cancer survival: by tumour type and tumour stage

4.2.1. Thyroid cancer survival by type, clinical stage (cStage) and sex: number at risk and net survival probabilities, 2015-2024

			Net Survival Probability, 2015-2024					
Type	**cStage**	**N at risk**	**1-y (95%CI)**	**2-y (95%CI)**	**3-y (95%CI)**	**4-y (95%CI)**	**5-y (95%CI)**	**10-y (95%CI)**
Total		9,991	96.7% (96.3%; 97.1%)	96.1% (95.6%; 96.6%)	95.8% (95.3%; 96.4%)	95.5% (94.8%; 96.1%)	95.2% (94.5%; 95.9%)	94.7% (92.1%; 97.3%)
Males								
Papillary carcinoma <55y	All	973	99.6% (99.1%; 100.1%)	99.4% (98.8%; 100.1%)	99.6% (98.9%; 100.3%)	99.4% (98.6%; 100.3%)	98.9% (97.8%; 100.0%)	99.0% (97.2%; 100.9%)
	I	579	99.6% (99.0%; 100.2%)	99.5% (98.8%; 100.3%)	99.5% (98.6%; 100.4%)	99.2% (98.1%; 100.4%)	98.8% (97.3%; 100.3%)	98.6% (94.9%; 102.4%)
	II	20	N<50	N<50	N<50	N<50	N<50	N<50
	III	4	N<50	N<50	N<50	N<50	N<50	N<50
	IV	3	N<50	N<50	N<50	N<50	N<50	N<50
	X/NA	367	99.4% (98.5%; 100.3%)	99.7% (98.8%; 100.6%)	100.0% (99.1%; 100.9%)	100.0% (98.9%; 101.1%)	99.4% (97.8%; 101.0%)	99.0% (96.4%; 101.7%)
Papillary carcinoma 55+y	All	1,065	98.7% (97.6%; 99.9%)	98.4% (96.8%; 99.9%)	97.0% (94.9%; 99.1%)	95.7% (93.1%; 98.3%)	96.3% (93.4%; 99.2%)	94.5% (88.0%; 101.5%)
	I	343	99.5% (97.9%; 101.2%)	98.3% (95.6%; 101.1%)	98.0% (94.6%; 101.6%)	98.6% (94.5%; 102.9%)	100.0% (95.3%; 105.0%)	93.9% (74.0%; 119.3%)
	II	124	96.9% (93.0%; 100.9%)	94.7% (89.3%; 100.4%)	94.5% (88.6%; 100.9%)	95.8% (89.4%; 102.7%)	95.4% (88.1%; 103.2%)	104.0% (92.2%; 117.3%)
	III	20	N<50	N<50	N<50	N<50	N<50	N<50
	IV	52	87.5% (77.9%; 98.3%)	82.3% (70.8%; 95.7%)	73.9% (60.8%; 89.8%)	69.4% (55.1%; 87.5%)	59.6% (44.4%; 80.0%)	24.5% (11.4%; 52.9%)
	X/NA	526	99.6% (98.2%; 101.0%)	101.0% (99.3%; 102.8%)	99.0% (96.4%; 101.8%)	96.8% (93.4%; 100.5%)	98.2% (94.4%; 102.1%)	97.9% (90.1%; 106.5%)
Follicular carcinoma <55y	All	134	98.7% (96.7%; 100.8%)	97.4% (94.6%; 100.4%)	96.9% (93.6%; 100.2%)	96.2% (92.6%; 100.0%)	95.4% (91.2%; 99.7%)	94.5% (89.2%; 100.1%)
	I	79	97.6% (94.3%; 101.2%)	96.6% (92.5%; 100.9%)	95.4% (90.5%; 100.5%)	95.5% (90.7%; 100.6%)	95.8% (90.9%; 100.9%)	94.7% (88.3%; 101.5%)
	III	5	N<50	N<50	N<50	N<50	N<50	N<50
	X/NA	50	100.0% (100.0%; 100.0%)	98.4% (94.7%; 102.4%)	98.7% (94.9%; 102.6%)	96.6% (90.7%; 103.0%)	93.7% (85.5%; 102.6%)	92.2% (82.2%; 103.4%)
Follicular carcinoma 55+y	All	310	95.7% (92.9%; 98.5%)	92.9% (89.0%; 97.0%)	91.7% (87.0%; 96.6%)	90.2% (84.6%; 96.1%)	92.0% (85.8%; 98.6%)	71.7% (35.6%; 144.3%)
	I	82	97.1% (93.1%; 101.3%)	91.4% (84.2%; 99.2%)	88.8% (80.2%; 98.3%)	91.4% (82.5%; 101.1%)	93.4% (84.3%; 103.4%)	FU<10y

Net Survival Probability, 2015-2024								
Type	**cStage**	**N at risk**	**1-y (95%CI)**	**2-y (95%CI)**	**3-y (95%CI)**	**4-y (95%CI)**	**5-y (95%CI)**	**10-y (95%CI)**
	II	69	98.5% (94.6%; 102.7%)	97.1% (90.6%; 104.0%)	96.2% (87.7%; 105.6%)	91.6% (80.6%; 104.1%)	94.5% (83.2%; 107.4%)	99.2% (81.8%; 120.3%)
	III	8	N<50	N<50	N<50	N<50	N<50	N<50
	IV	42	N<50	N<50	N<50	N<50	N<50	N<50
	X/NA	109	97.8% (93.8%; 101.9%)	97.3% (91.7%; 103.2%)	98.6% (92.2%; 105.5%)	97.1% (88.8%; 106.2%)	99.7% (90.3%; 110.1%)	64.6% (25.7%; 162.1%)
Medullary carcinoma	All	149	99.0% (96.4%; 101.7%)	94.6% (89.8%; 99.7%)	91.2% (85.1%; 97.7%)	90.7% (83.8%; 98.2%)	85.1% (74.8%; 96.8%)	74.3% (58.0%; 95.1%)
	I	22	N<50	N<50	N<50	N<50	N<50	N<50
	II	24	N<50	N<50	N<50	N<50	N<50	N<50
	III	19	N<50	N<50	N<50	N<50	N<50	N<50
	IV	44	N<50	N<50	N<50	N<50	N<50	N<50
	X/NA	40	N<50	N<50	N<50	N<50	N<50	N<50
Anaplastic carcinoma	All	101	29.7% (21.9%; 40.2%)	20.9% (14.1%; 30.8%)	19.1% (12.6%; 29.1%)	16.8% (10.5%; 26.8%)	18.2% (11.4%; 29.0%)	5.5% (1.2%; 25.0%)
	X/NA	10	N<50	N<50	N<50	N<50	N<50	N<50
Other	All	58	56.2% (44.7%; 70.7%)	54.3% (42.4%; 69.5%)	47.6% (35.3%; 64.2%)	46.9% (34.3%; 63.9%)	41.7% (29.2%; 59.7%)	31.1% (15.8%; 61.3%)
	I	4	N<50	N<50	N<50	N<50	N<50	N<50
	II	12	N<50	N<50	N<50	N<50	N<50	N<50
	III	2	N<50	N<50	N<50	N<50	N<50	N<50
	IV	15	N<50	N<50	N<50	N<50	N<50	N<50
	X/NA	25	N<50	N<50	N<50	N<50	N<50	N<50
Females								
Papillary carcinoma <55y	All	3,590	99.8% (99.7%; 100.0%)	99.8% (99.6%; 100.0%)	99.8% (99.6%; 100.1%)	99.6% (99.3%; 99.9%)	99.6% (99.3%; 100.0%)	100.0% (99.4%; 100.6%)
	I	2,134	99.9% (99.7%; 100.1%)	99.9% (99.6%; 100.1%)	99.9% (99.6%; 100.2%)	99.7% (99.2%; 100.1%)	99.6% (99.1%; 100.1%)	99.8% (99.1%; 100.6%)
	II	24	N<50	N<50	N<50	N<50	N<50	N<50
	III	7	N<50	N<50	N<50	N<50	N<50	N<50
	IV	3	N<50	N<50	N<50	N<50	N<50	N<50

Net Survival Probability, 2015-2024								
Type	**cStage**	**N at risk**	**1-y (95%CI)**	**2-y (95%CI)**	**3-y (95%CI)**	**4-y (95%CI)**	**5-y (95%CI)**	**10-y (95%CI)**
	X/NA	1,422	99.9% (99.6%; 100.1%)	99.8% (99.4%; 100.2%)	99.8% (99.4%; 100.2%)	99.7% (99.2%; 100.2%)	99.9% (99.4%; 100.4%)	100.3% (99.5%; 101.1%)
Papillary carcinoma 55+y	All	2,348	98.8% (98.2%; 99.5%)	98.7% (97.9%; 99.6%)	99.1% (98.1%; 100.2%)	99.5% (98.3%; 100.7%)	99.2% (97.7%; 100.8%)	104.4% (100.7%; 108.3%)
	I	841	99.7% (98.9%; 100.5%)	99.4% (98.2%; 100.7%)	99.5% (98.0%; 101.1%)	100.1% (98.3%; 101.9%)	101.0% (98.9%; 103.2%)	125.2% (119.4%; 131.2%)
	II	167	97.6% (94.3%; 100.9%)	98.8% (95.2%; 102.5%)	99.3% (95.0%; 103.8%)	98.7% (92.8%; 104.9%)	96.8% (89.5%; 104.6%)	95.2% (82.7%; 109.6%)
	III	33	N<50	N<50	N<50	N<50	N<50	N<50
	IV	56	73.3% (62.3%; 86.4%)	66.3% (54.0%; 81.4%)	59.5% (46.3%; 76.4%)	57.5% (43.8%; 75.4%)	58.9% (44.4%; 78.3%)	37.6% (15.2%; 93.0%)
	X/NA	1,251	99.7% (99.0%; 100.4%)	100.0% (99.0%; 101.0%)	100.8% (99.6%; 101.9%)	101.4% (100.0%; 102.8%)	100.6% (98.7%; 102.5%)	103.9% (99.7%; 108.3%)
Follicular carcinoma <55y	All	375	99.6% (98.8%; 100.3%)	99.7% (99.0%; 100.4%)	99.2% (98.1%; 100.4%)	99.0% (97.8%; 100.3%)	98.8% (97.3%; 100.3%)	97.2% (94.4%; 100.2%)
	I	206	99.1% (97.8%; 100.5%)	99.3% (97.9%; 100.6%)	99.4% (98.1%; 100.7%)	99.5% (98.2%; 100.9%)	99.7% (98.3%; 101.0%)	97.9% (94.1%; 101.8%)
	II	12	N<50	N<50	N<50	N<50	N<50	N<50
	X/NA	157	100.1% (100.1%; 100.1%)	100.2% (100.2%; 100.2%)	98.9% (96.9%; 100.9%)	98.2% (95.7%; 100.8%)	97.5% (94.5%; 100.6%)	98.6% (95.6%; 101.8%)
Follicular carcinoma 55+y	All	421	95.5% (93.0%; 98.0%)	94.5% (91.4%; 97.7%)	93.1% (89.3%; 97.1%)	90.8% (85.9%; 95.9%)	87.3% (81.0%; 94.1%)	70.7% (50.1%; 99.8%)
	I	107	99.7% (97.8%; 101.8%)	100.6% (97.2%; 104.2%)	100.2% (95.1%; 105.5%)	99.0% (92.4%; 106.1%)	98.8% (90.9%; 107.3%)	81.1% (58.1%; 113.3%)
	II	68	96.1% (90.4%; 102.1%)	95.9% (89.0%; 103.4%)	94.9% (86.4%; 104.2%)	95.6% (85.6%; 106.9%)	94.9% (83.0%; 108.5%)	96.8% (74.3%; 126.0%)
	III	9	N<50	N<50	N<50	N<50	N<50	N<50
	IV	54	73.7% (62.2%; 87.4%)	66.6% (53.7%; 82.6%)	59.3% (45.4%; 77.4%)	60.4% (45.8%; 79.7%)	43.8% (25.7%; 74.6%)	FU<10y
	X/NA	183	99.1% (96.5%; 101.7%)	100.1% (96.7%; 103.6%)	99.4% (94.9%; 104.1%)	93.8% (86.6%; 101.6%)	93.3% (84.8%; 102.7%)	73.5% (46.5%; 116.4%)
Medullary carcinoma	All	208	98.3% (95.9%; 100.6%)	95.7% (92.3%; 99.3%)	96.7% (93.0%; 100.5%)	97.5% (93.5%; 101.6%)	95.5% (90.3%; 101.0%)	89.3% (77.7%; 102.6%)
	I	66	100.0% (100.0%; 100.0%)	101.8% (101.8%; 101.8%)	103.2% (103.2%; 103.2%)	104.5% (104.5%; 104.5%)	105.8% (105.8%; 105.8%)	118.9% (118.9%; 118.9%)
	II	21	N<50	N<50	N<50	N<50	N<50	N<50
	III	4	N<50	N<50	N<50	N<50	N<50	N<50
	IV	38	N<50	N<50	N<50	N<50	N<50	N<50
	X/NA	79	97.3% (93.1%; 101.7%)	97.4% (92.6%; 102.6%)	97.9% (92.3%; 103.9%)	98.2% (91.8%; 105.1%)	98.1% (90.4%; 106.4%)	88.1% (72.0%; 107.8%)
Anaplastic carcinoma	All	130	19.7% (13.9%; 28.0%)	13.2% (8.4%; 20.7%)	11.3% (6.8%; 18.7%)	9.0% (5.0%; 16.3%)	9.1% (5.0%; 16.4%)	FU<10y

Net Survival Probability, 2015-2024								
Type	**cStage**	**N at risk**	**1-y (95%CI)**	**2-y (95%CI)**	**3-y (95%CI)**	**4-y (95%CI)**	**5-y (95%CI)**	**10-y (95%CI)**
	X/NA	11	N<50	N<50	N<50	N<50	N<50	N<50
Other	All	135	70.0% (62.5%; 78.5%)	67.3% (59.4%; 76.2%)	63.7% (55.4%; 73.3%)	62.9% (54.4%; 72.9%)	61.3% (52.0%; 72.3%)	62.5% (50.7%; 77.1%)
	I	18	N<50	N<50	N<50	N<50	N<50	N<50
	II	6	N<50	N<50	N<50	N<50	N<50	N<50
	III	3	N<50	N<50	N<50	N<50	N<50	N<50
	IV	34	N<50	N<50	N<50	N<50	N<50	N<50
	X/NA	74	77.8% (68.7%; 88.2%)	78.0% (68.5%; 88.8%)	73.7% (63.1%; 86.0%)	72.9% (61.9%; 85.9%)	70.8% (58.3%; 85.9%)	80.4% (66.3%; 97.6%)

Note: Survival results obtained on very small groups are considered to be too uncertain, therefore a minimum size threshold of 50 is applied in the reporting of the Net Survival estimation.

Note: Survival results are not shown due to limited follow-up throughout the period, as indicated by FU<*k*years in the table.

4.2.2. Thyroid cancer survival by type, pathological stage (pStage) and sex: number at risk and net survival probabilities, 2015-2024

			Net Survival Probability, 2015-2024					
Type	**pStage**	**N at risk**	**1-y (95%CI)**	**2-y (95%CI)**	**3-y (95%CI)**	**4-y (95%CI)**	**5-y (95%CI)**	**10-y (95%CI)**
Total		9,991	96.7% (96.3%; 97.1%)	96.1% (95.6%; 96.6%)	95.8% (95.3%; 96.4%)	95.5% (94.8%; 96.1%)	95.2% (94.5%; 95.9%)	94.7% (92.1%; 97.3%)
Males								
Papillary carcinoma <55y	All	973	99.6% (99.1%; 100.1%)	99.4% (98.8%; 100.1%)	99.6% (98.9%; 100.3%)	99.4% (98.6%; 100.3%)	98.9% (97.8%; 100.0%)	99.0% (97.2%; 100.9%)
	I	904	99.6% (99.1%; 100.1%)	99.7% (99.1%; 100.2%)	99.8% (99.1%; 100.4%)	99.7% (99.0%; 100.5%)	99.3% (98.3%; 100.4%)	99.2% (97.3%; 101.2%)
	II	15	N<50	N<50	N<50	N<50	N<50	N<50
	III	14	N<50	N<50	N<50	N<50	N<50	N<50
	IV	11	N<50	N<50	N<50	N<50	N<50	N<50
	X/NA	29	N<50	N<50	N<50	N<50	N<50	N<50
Papillary carcinoma 55+y	All	1,065	98.7% (97.6%; 99.9%)	98.4% (96.8%; 99.9%)	97.0% (94.9%; 99.1%)	95.7% (93.1%; 98.3%)	96.3% (93.4%; 99.2%)	94.5% (88.0%; 101.5%)
	I	682	100.8% (99.9%; 101.6%)	101.9% (100.6%; 103.2%)	101.3% (99.4%; 103.3%)	101.0% (98.4%; 103.7%)	102.4% (99.4%; 105.5%)	102.0% (93.4%; 111.5%)
	II	206	100.0% (98.0%; 102.0%)	98.9% (95.6%; 102.2%)	98.1% (93.8%; 102.6%)	95.2% (89.6%; 101.3%)	94.6% (88.2%; 101.5%)	101.3% (88.3%; 116.3%)
	III	62	99.4% (95.0%; 103.9%)	101.7% (97.2%; 106.3%)	98.1% (90.1%; 106.8%)	99.9% (90.5%; 110.2%)	100.7% (90.3%; 112.3%)	95.1% (77.1%; 117.3%)
	IV	36	N<50	N<50	N<50	N<50	N<50	N<50
	X/NA	79	75.4% (65.6%; 86.6%)	64.1% (53.0%; 77.5%)	56.9% (45.1%; 71.7%)	51.0% (38.7%; 67.0%)	49.8% (37.6%; 66.1%)	61.2% (46.1%; 81.1%)
Follicular carcinoma <55y	All	134	98.7% (96.7%; 100.8%)	97.4% (94.6%; 100.4%)	96.9% (93.6%; 100.2%)	96.2% (92.6%; 100.0%)	95.4% (91.2%; 99.7%)	94.5% (89.2%; 100.1%)
	I	110	98.4% (95.9%; 100.9%)	97.7% (94.7%; 100.8%)	96.8% (93.3%; 100.5%)	96.0% (91.9%; 100.2%)	96.3% (92.2%; 100.5%)	96.1% (91.0%; 101.4%)
	II	2	N<50	N<50	N<50	N<50	N<50	N<50
	III	8	N<50	N<50	N<50	N<50	N<50	N<50
	X/NA	14	N<50	N<50	N<50	N<50	N<50	N<50
Follicular carcinoma 55+y	All	310	95.7% (92.9%; 98.5%)	92.9% (89.0%; 97.0%)	91.7% (87.0%; 96.6%)	90.2% (84.6%; 96.1%)	92.0% (85.8%; 98.6%)	71.7% (35.6%; 144.3%)
	I	94	98.2% (94.7%; 101.9%)	96.6% (91.2%; 102.3%)	94.9% (87.9%; 102.4%)	97.6% (90.5%; 105.4%)	98.1% (89.7%; 107.3%)	FU<10y
	II	118	97.2% (93.2%; 101.3%)	95.7% (89.9%; 101.8%)	94.2% (87.0%; 102.0%)	93.2% (84.8%; 102.4%)	97.8% (89.0%; 107.5%)	90.2% (60.8%; 133.7%)

Net Survival Probability, 2015-2024								
Type	**pStage**	**N at risk**	**1-y (95%CI)**	**2-y (95%CI)**	**3-y (95%CI)**	**4-y (95%CI)**	**5-y (95%CI)**	**10-y (95%CI)**
	III	25	N<50	N<50	N<50	N<50	N<50	N<50
	IV	22	N<50	N<50	N<50	N<50	N<50	N<50
	X/NA	51	85.6% (76.1%; 96.4%)	82.3% (71.0%; 95.4%)	79.0% (65.8%; 94.7%)	75.2% (60.7%; 93.2%)	76.6% (61.9%; 95.0%)	72.7% (51.8%; 101.9%)
Medullary carcinoma	All	149	99.0% (96.4%; 101.7%)	94.6% (89.8%; 99.7%)	91.2% (85.1%; 97.7%)	90.7% (83.8%; 98.2%)	85.1% (74.8%; 96.8%)	74.3% (58.0%; 95.1%)
	I	35	N<50	N<50	N<50	N<50	N<50	N<50
	II	23	N<50	N<50	N<50	N<50	N<50	N<50
	III	23	N<50	N<50	N<50	N<50	N<50	N<50
	IV	51	97.7% (92.4%; 103.3%)	88.3% (78.8%; 99.0%)	83.5% (71.9%; 96.9%)	84.3% (72.6%; 97.8%)	84.0% (71.3%; 99.1%)	85.1% (61.8%; 117.1%)
	X/NA	17	N<50	N<50	N<50	N<50	N<50	N<50
Anaplastic carcinoma	All	101	29.7% (21.9%; 40.2%)	20.9% (14.1%; 30.8%)	19.1% (12.6%; 29.1%)	16.8% (10.5%; 26.8%)	18.2% (11.4%; 29.0%)	5.5% (1.2%; 25.0%)
	X/NA	10	N<50	N<50	N<50	N<50	N<50	N<50
Other	All	58	56.2% (44.7%; 70.7%)	54.3% (42.4%; 69.5%)	47.6% (35.3%; 64.2%)	46.9% (34.3%; 63.9%)	41.7% (29.2%; 59.7%)	31.1% (15.8%; 61.3%)
	I	8	N<50	N<50	N<50	N<50	N<50	N<50
	II	8	N<50	N<50	N<50	N<50	N<50	N<50
	IV	2	N<50	N<50	N<50	N<50	N<50	N<50
	X/NA	40	N<50	N<50	N<50	N<50	N<50	N<50
Females								
Papillary carcinoma <55y	All	3,590	99.8% (99.7%; 100.0%)	99.8% (99.6%; 100.0%)	99.8% (99.6%; 100.1%)	99.6% (99.3%; 99.9%)	99.6% (99.3%; 100.0%)	100.0% (99.4%; 100.6%)
	I	3,411	99.9% (99.8%; 100.1%)	99.9% (99.6%; 100.1%)	99.9% (99.6%; 100.1%)	99.7% (99.3%; 100.0%)	99.7% (99.3%; 100.1%)	100.2% (99.7%; 100.7%)
	II	27	N<50	N<50	N<50	N<50	N<50	N<50
	III	40	N<50	N<50	N<50	N<50	N<50	N<50
	IV	9	N<50	N<50	N<50	N<50	N<50	N<50
	X/NA	103	97.1% (93.9%; 100.5%)	97.3% (94.0%; 100.6%)	97.4% (94.1%; 100.8%)	97.5% (94.3%; 100.9%)	97.7% (94.4%; 101.1%)	95.0% (89.1%; 101.3%)
Papillary carcinoma 55+y	All	2,348	98.8% (98.2%; 99.5%)	98.7% (97.9%; 99.6%)	99.1% (98.1%; 100.2%)	99.5% (98.3%; 100.7%)	99.2% (97.7%; 100.8%)	104.4% (100.7%; 108.3%)

Net Survival Probability, 2015-2024												
Type	**pStage**	**N at risk**	**1-y (95%CI)**		**2-y (95%CI)**		**3-y (95%CI)**		**4-y (95%CI)**		**5-y (95%CI)**		**10-y (95%CI)**	
	I	1,714	100.2%	(99.7%; 100.7%)	100.4%	(99.7%; 101.2%)	101.2%	(100.4%; 102.1%)	102.0%	(100.9%; 103.0%)	102.4%	(101.1%; 103.7%)	110.6%	(107.0%; 114.4%)
	II	347	98.3%	(96.4%; 100.2%)	98.1%	(95.7%; 100.5%)	97.6%	(94.6%; 100.7%)	96.8%	(93.1%; 100.6%)	95.0%	(90.5%; 99.8%)	95.3%	(88.0%; 103.1%)
	III	117	96.5%	(92.5%; 100.7%)	98.0%	(93.3%; 102.9%)	99.5%	(94.1%; 105.2%)	102.0%	(96.2%; 108.2%)	101.0%	(92.9%; 109.9%)	95.7%	(79.3%; 115.6%)
	IV	43	N<50		N<50		N<50		N<50		N<50		N<50	
	X/NA	127	85.8%	(79.3%; 92.8%)	82.0%	(74.4%; 90.4%)	80.7%	(72.3%; 90.1%)	78.0%	(68.6%; 88.6%)	76.0%	(65.6%; 88.1%)	85.0%	(64.4%; 112.3%)
Follicular carcinoma <55y	All	375	99.6%	(98.8%; 100.3%)	99.7%	(99.0%; 100.4%)	99.2%	(98.1%; 100.4%)	99.0%	(97.8%; 100.3%)	98.8%	(97.3%; 100.3%)	97.2%	(94.4%; 100.2%)
	I	305	99.8%	(99.1%; 100.4%)	99.9%	(99.3%; 100.5%)	99.7%	(98.7%; 100.6%)	99.8%	(98.8%; 100.8%)	99.4%	(98.0%; 100.8%)	97.9%	(94.8%; 101.0%)
	II	17	N<50		N<50		N<50		N<50		N<50		N<50	
	III	1	N<50		N<50		N<50		N<50		N<50		N<50	
	IV	2	N<50		N<50		N<50		N<50		N<50		N<50	
	X/NA	50	98.0%	(94.3%; 102.0%)	98.2%	(94.4%; 102.1%)	95.6%	(89.5%; 102.1%)	93.0%	(85.3%; 101.4%)	93.1%	(85.4%; 101.5%)	93.9%	(86.1%; 102.4%)
Follicular carcinoma 55+y	All	421	95.5%	(93.0%; 98.0%)	94.5%	(91.4%; 97.7%)	93.1%	(89.3%; 97.1%)	90.8%	(85.9%; 95.9%)	87.3%	(81.0%; 94.1%)	70.7%	(50.1%; 99.8%)
	I	172	99.5%	(97.8%; 101.2%)	101.1%	(98.6%; 103.7%)	102.7%	(99.5%; 105.9%)	101.0%	(96.0%; 106.3%)	101.2%	(95.1%; 107.8%)	78.5%	(53.4%; 115.3%)
	II	129	98.0%	(94.3%; 101.8%)	99.8%	(95.2%; 104.7%)	98.1%	(91.8%; 104.7%)	95.4%	(86.3%; 105.4%)	93.7%	(82.4%; 106.5%)	72.6%	(39.4%; 133.6%)
	III	19	N<50		N<50		N<50		N<50		N<50		N<50	
	IV	30	N<50		N<50		N<50		N<50		N<50		N<50	
	X/NA	71	85.6%	(77.1%; 95.1%)	75.0%	(64.4%; 87.4%)	69.3%	(57.8%; 83.2%)	65.8%	(53.3%; 81.2%)	64.1%	(50.6%; 81.2%)	64.5%	(47.5%; 87.5%)
Medullary carcinoma	All	208	98.3%	(95.9%; 100.6%)	95.7%	(92.3%; 99.3%)	96.7%	(93.0%; 100.5%)	97.5%	(93.5%; 101.6%)	95.5%	(90.3%; 101.0%)	89.3%	(77.7%; 102.6%)
	I	91	100.0%	(100.0%; 100.0%)	102.1%	(102.1%; 102.1%)	103.7%	(103.7%; 103.7%)	105.5%	(105.5%; 105.5%)	104.9%	(100.7%; 109.3%)	99.2%	(82.4%; 119.6%)
	II	29	N<50		N<50		N<50		N<50		N<50		N<50	
	III	26	N<50		N<50		N<50		N<50		N<50		N<50	
	IV	46	N<50		N<50		N<50		N<50		N<50		N<50	
	X/NA	16	N<50		N<50		N<50		N<50		N<50		N<50	
Anaplastic carcinoma	All	130	19.7%	(13.9%; 28.0%)	13.2%	(8.4%; 20.7%)	11.3%	(6.8%; 18.7%)	9.0%	(5.0%; 16.3%)	9.1%	(5.0%; 16.4%)	FU<10y	

Net Survival Probability, 2015-2024								
Type	**pStage**	**N at risk**	**1-y (95%CI)**	**2-y (95%CI)**	**3-y (95%CI)**	**4-y (95%CI)**	**5-y (95%CI)**	**10-y (95%CI)**
	X/NA	11	N<50	N<50	N<50	N<50	N<50	N<50
Other	All	135	70.0% (62.5%; 78.5%)	67.3% (59.4%; 76.2%)	63.7% (55.4%; 73.3%)	62.9% (54.4%; 72.9%)	61.3% (52.0%; 72.3%)	62.5% (50.7%; 77.1%)
	I	36	N<50	N<50	N<50	N<50	N<50	N<50
	II	7	N<50	N<50	N<50	N<50	N<50	N<50
	III	2	N<50	N<50	N<50	N<50	N<50	N<50
	IV	12	N<50	N<50	N<50	N<50	N<50	N<50
	X/NA	78	56.6% (46.3%; 69.1%)	51.2% (40.7%; 64.3%)	44.4% (33.8%; 58.2%)	42.3% (31.7%; 56.6%)	38.7% (27.7%; 54.3%)	41.4% (29.1%; 58.7%)

Note: Survival results obtained on very small groups are considered to be too uncertain, therefore a minimum size threshold of 50 is applied in the reporting of the Net Survival estimation.

Note: Survival results are not shown due to limited follow-up throughout the period, as indicated by FU<*k*years in the table.

4.2.3. Thyroid cancer survival by type, stage and sex: number at risk and net survival probabilities, 2015-2024

			Net Survival Probability, 2015-2024					
Type	**Stage**	**N at risk**	**1-y (95%CI)**	**2-y (95%CI)**	**3-y (95%CI)**	**4-y (95%CI)**	**5-y (95%CI)**	**10-y (95%CI)**
Total		9,991	96.7% (96.3%; 97.1%)	96.1% (95.6%; 96.6%)	95.8% (95.3%; 96.4%)	95.5% (94.8%; 96.1%)	95.2% (94.5%; 95.9%)	94.7% (92.1%; 97.3%)
Males								
Papillary carcinoma <55y	All	973	99.6% (99.1%; 100.1%)	99.4% (98.8%; 100.1%)	99.6% (98.9%; 100.3%)	99.4% (98.6%; 100.3%)	98.9% (97.8%; 100.0%)	99.0% (97.2%; 100.9%)
	I	903	99.5% (99.0%; 100.0%)	99.5% (98.9%; 100.2%)	99.7% (99.0%; 100.3%)	99.6% (98.8%; 100.4%)	99.2% (98.1%; 100.3%)	99.1% (97.2%; 101.1%)
	II	27	N<50	N<50	N<50	N<50	N<50	N<50
	III	14	N<50	N<50	N<50	N<50	N<50	N<50
	IV	12	N<50	N<50	N<50	N<50	N<50	N<50
	X/NA	17	N<50	N<50	N<50	N<50	N<50	N<50
Papillary carcinoma 55+y	All	1,065	98.7% (97.6%; 99.9%)	98.4% (96.8%; 99.9%)	97.0% (94.9%; 99.1%)	95.7% (93.1%; 98.3%)	96.3% (93.4%; 99.2%)	94.5% (88.0%; 101.5%)
	I	692	100.4% (99.4%; 101.4%)	101.1% (99.6%; 102.5%)	100.4% (98.3%; 102.5%)	99.7% (96.9%; 102.6%)	101.1% (97.9%; 104.3%)	100.7% (92.2%; 110.1%)
	II	202	99.5% (97.3%; 101.8%)	97.2% (93.4%; 101.1%)	97.6% (93.1%; 102.3%)	94.6% (88.8%; 100.8%)	94.8% (88.4%; 101.7%)	102.7% (89.6%; 117.6%)
	III	62	96.6% (91.3%; 102.2%)	98.2% (91.6%; 105.3%)	95.7% (86.9%; 105.3%)	97.9% (87.8%; 109.2%)	98.6% (87.6%; 111.0%)	92.8% (74.8%; 115.1%)
	IV	66	90.7% (82.9%; 99.2%)	87.3% (77.8%; 97.9%)	78.5% (67.0%; 91.9%)	75.1% (62.7%; 90.1%)	68.8% (55.3%; 85.5%)	40.0% (25.1%; 63.6%)
	X/NA	43	N<50	N<50	N<50	N<50	N<50	N<50
Follicular carcinoma <55y	All	134	98.7% (96.7%; 100.8%)	97.4% (94.6%; 100.4%)	96.9% (93.6%; 100.2%)	96.2% (92.6%; 100.0%)	95.4% (91.2%; 99.7%)	94.5% (89.2%; 100.1%)
	I	111	98.4% (96.0%; 100.9%)	97.7% (94.7%; 100.8%)	96.9% (93.4%; 100.6%)	96.0% (91.9%; 100.2%)	96.3% (92.2%; 100.5%)	96.1% (91.1%; 101.4%)
	II	2	N<50	N<50	N<50	N<50	N<50	N<50
	III	9	N<50	N<50	N<50	N<50	N<50	N<50
	X/NA	12	N<50	N<50	N<50	N<50	N<50	N<50
Follicular carcinoma 55+y	All	310	95.7% (92.9%; 98.5%)	92.9% (89.0%; 97.0%)	91.7% (87.0%; 96.6%)	90.2% (84.6%; 96.1%)	92.0% (85.8%; 98.6%)	71.7% (35.6%; 144.3%)
	I	99	97.4% (93.5%; 101.4%)	93.9% (87.8%; 100.3%)	92.4% (85.1%; 100.3%)	95.1% (87.5%; 103.2%)	97.9% (90.1%; 106.3%)	FU<10y
	II	112	97.6% (93.8%; 101.6%)	96.6% (91.2%; 102.2%)	96.1% (89.4%; 103.4%)	94.5% (86.2%; 103.5%)	98.4% (89.8%; 107.8%)	89.5% (60.4%; 132.6%)

Net Survival Probability, 2015-2024								
Type	**Stage**	**N at risk**	**1-y (95%CI)**	**2-y (95%CI)**	**3-y (95%CI)**	**4-y (95%CI)**	**5-y (95%CI)**	**10-y (95%CI)**
	III	25	N<50	N<50	N<50	N<50	N<50	N<50
	IV	47	N<50	N<50	N<50	N<50	N<50	N<50
	X/NA	27	N<50	N<50	N<50	N<50	N<50	N<50
Medullary carcinoma	All	149	99.0% (96.4%; 101.7%)	94.6% (89.8%; 99.7%)	91.2% (85.1%; 97.7%)	90.7% (83.8%; 98.2%)	85.1% (74.8%; 96.8%)	74.3% (58.0%; 95.1%)
	I	35	N<50	N<50	N<50	N<50	N<50	N<50
	II	23	N<50	N<50	N<50	N<50	N<50	N<50
	III	21	N<50	N<50	N<50	N<50	N<50	N<50
	IV	64	97.2% (91.9%; 102.7%)	85.2% (75.6%; 95.9%)	80.3% (69.2%; 93.1%)	76.9% (64.5%; 91.6%)	74.3% (60.7%; 91.0%)	83.1% (62.7%; 110.1%)
	X/NA	6	N<50	N<50	N<50	N<50	N<50	N<50
Anaplastic carcinoma	All	101	29.7% (21.9%; 40.2%)	20.9% (14.1%; 30.8%)	19.1% (12.6%; 29.1%)	16.8% (10.5%; 26.8%)	18.2% (11.4%; 29.0%)	5.5% (1.2%; 25.0%)
	X/NA	10	N<50	N<50	N<50	N<50	N<50	N<50
Other	All	58	56.2% (44.7%; 70.7%)	54.3% (42.4%; 69.5%)	47.6% (35.3%; 64.2%)	46.9% (34.3%; 63.9%)	41.7% (29.2%; 59.7%)	31.1% (15.8%; 61.3%)
	I	10	N<50	N<50	N<50	N<50	N<50	N<50
	II	14	N<50	N<50	N<50	N<50	N<50	N<50
	III	2	N<50	N<50	N<50	N<50	N<50	N<50
	IV	17	N<50	N<50	N<50	N<50	N<50	N<50
	X/NA	15	N<50	N<50	N<50	N<50	N<50	N<50
Females								
Papillary carcinoma <55y	All	3,590	99.8% (99.7%; 100.0%)	99.8% (99.6%; 100.0%)	99.8% (99.6%; 100.1%)	99.6% (99.3%; 99.9%)	99.6% (99.3%; 100.0%)	100.0% (99.4%; 100.6%)
	I	3,425	99.9% (99.7%; 100.0%)	99.8% (99.6%; 100.1%)	99.8% (99.6%; 100.1%)	99.7% (99.4%; 100.0%)	99.7% (99.4%; 100.1%)	100.3% (99.8%; 100.8%)
	II	42	N<50	N<50	N<50	N<50	N<50	N<50
	III	40	N<50	N<50	N<50	N<50	N<50	N<50
	IV	9	N<50	N<50	N<50	N<50	N<50	N<50
	X/NA	74	98.7% (96.0%; 101.4%)	98.9% (96.2%; 101.6%)	99.0% (96.3%; 101.7%)	99.1% (96.5%; 101.9%)	99.3% (96.6%; 102.1%)	95.9% (89.4%; 102.9%)

Net Survival Probability, 2015-2024								
Type	**Stage**	**N at risk**	**1-y (95%CI)**	**2-y (95%CI)**	**3-y (95%CI)**	**4-y (95%CI)**	**5-y (95%CI)**	**10-y (95%CI)**
Papillary carcinoma 55+y	All	2,348	98.8% (98.2%; 99.5%)	98.7% (97.9%; 99.6%)	99.1% (98.1%; 100.2%)	99.5% (98.3%; 100.7%)	99.2% (97.7%; 100.8%)	104.4% (100.7%; 108.3%)
	I	1,737	100.1% (99.6%; 100.6%)	100.2% (99.5%; 101.0%)	101.0% (100.2%; 101.9%)	101.8% (100.7%; 102.8%)	102.1% (100.8%; 103.5%)	110.7% (107.1%; 114.4%)
	II	349	98.1% (96.1%; 100.1%)	98.6% (96.2%; 101.0%)	97.8% (94.8%; 101.0%)	96.2% (92.1%; 100.4%)	94.4% (89.6%; 99.5%)	95.6% (88.3%; 103.4%)
	III	118	96.3% (92.3%; 100.4%)	96.3% (91.0%; 101.8%)	98.5% (92.8%; 104.6%)	101.0% (94.9%; 107.5%)	100.0% (91.7%; 109.1%)	94.8% (78.4%; 114.6%)
	IV	70	77.6% (68.1%; 88.5%)	71.1% (60.2%; 83.9%)	66.4% (54.7%; 80.7%)	62.4% (49.9%; 77.9%)	64.3% (51.1%; 80.9%)	46.3% (24.9%; 86.3%)
	X/NA	74	93.9% (87.8%; 100.5%)	93.2% (85.7%; 101.3%)	90.8% (81.8%; 100.8%)	90.3% (80.7%; 101.1%)	86.0% (74.1%; 99.8%)	102.3% (86.7%; 120.8%)
Follicular carcinoma <55y	All	375	99.6% (98.8%; 100.3%)	99.7% (99.0%; 100.4%)	99.2% (98.1%; 100.4%)	99.0% (97.8%; 100.3%)	98.8% (97.3%; 100.3%)	97.2% (94.4%; 100.2%)
	I	308	99.5% (98.6%; 100.4%)	99.6% (98.7%; 100.5%)	99.3% (98.2%; 100.5%)	99.5% (98.3%; 100.6%)	99.1% (97.6%; 100.6%)	98.5% (96.0%; 101.1%)
	II	21	N<50	N<50	N<50	N<50	N<50	N<50
	III	1	N<50	N<50	N<50	N<50	N<50	N<50
	IV	2	N<50	N<50	N<50	N<50	N<50	N<50
	X/NA	43	N<50	N<50	N<50	N<50	N<50	N<50
Follicular carcinoma 55+y	All	421	95.5% (93.0%; 98.0%)	94.5% (91.4%; 97.7%)	93.1% (89.3%; 97.1%)	90.8% (85.9%; 95.9%)	87.3% (81.0%; 94.1%)	70.7% (50.1%; 99.8%)
	I	176	99.5% (97.9%; 101.2%)	101.1% (98.8%; 103.6%)	102.8% (99.8%; 105.9%)	100.3% (95.1%; 105.8%)	99.2% (92.5%; 106.3%)	82.4% (58.9%; 115.2%)
	II	123	97.6% (93.7%; 101.6%)	100.0% (95.4%; 104.8%)	97.7% (91.4%; 104.5%)	94.2% (84.9%; 104.5%)	94.4% (83.5%; 106.8%)	75.3% (41.6%; 136.1%)
	III	21	N<50	N<50	N<50	N<50	N<50	N<50
	IV	62	72.5% (61.6%; 85.3%)	66.3% (54.3%; 81.0%)	58.3% (45.5%; 74.8%)	59.4% (45.9%; 76.8%)	43.3% (27.0%; 69.6%)	FU<10y
	X/NA	39	N<50	N<50	N<50	N<50	N<50	N<50
Medullary carcinoma	All	208	98.3% (95.9%; 100.6%)	95.7% (92.3%; 99.3%)	96.7% (93.0%; 100.5%)	97.5% (93.5%; 101.6%)	95.5% (90.3%; 101.0%)	89.3% (77.7%; 102.6%)
	I	92	100.0% (100.0%; 100.0%)	102.1% (102.1%; 102.1%)	103.7% (103.7%; 103.7%)	105.5% (105.5%; 105.5%)	105.0% (100.8%; 109.4%)	99.3% (82.4%; 119.6%)
	II	29	N<50	N<50	N<50	N<50	N<50	N<50
	III	24	N<50	N<50	N<50	N<50	N<50	N<50
	IV	56	94.2% (87.5%; 101.4%)	81.6% (71.2%; 93.5%)	82.9% (72.4%; 95.0%)	84.2% (73.5%; 96.4%)	73.9% (59.8%; 91.5%)	68.8% (49.0%; 96.6%)
	X/NA	7	N<50	N<50	N<50	N<50	N<50	N<50

Net Survival Probability, 2015-2024								
Type	**Stage**	**N at risk**	**1-y (95%CI)**	**2-y (95%CI)**	**3-y (95%CI)**	**4-y (95%CI)**	**5-y (95%CI)**	**10-y (95%CI)**
Anaplastic carcinoma	All	130	19.7% (13.9%; 28.0%)	13.2% (8.4%; 20.7%)	11.3% (6.8%; 18.7%)	9.0% (5.0%; 16.3%)	9.1% (5.0%; 16.4%)	FU<10y
	X/NA	11	N<50	N<50	N<50	N<50	N<50	N<50
Other	All	135	70.0% (62.5%; 78.5%)	67.3% (59.4%; 76.2%)	63.7% (55.4%; 73.3%)	62.9% (54.4%; 72.9%)	61.3% (52.0%; 72.3%)	62.5% (50.7%; 77.1%)
	I	39	N<50	N<50	N<50	N<50	N<50	N<50
	II	11	N<50	N<50	N<50	N<50	N<50	N<50
	III	4	N<50	N<50	N<50	N<50	N<50	N<50
	IV	37	N<50	N<50	N<50	N<50	N<50	N<50
	X/NA	44	N<50	N<50	N<50	N<50	N<50	N<50

Note: Survival results obtained on very small groups are considered to be too uncertain, therefore a minimum size threshold of 50 is applied in the reporting of the Net Survival estimation.

Note: Survival results are not shown due to limited follow-up throughout the period, as indicated by FU<*k*years in the table.

5.1. Thyroid cancer survival trends: by tumour type and tumour stage

5.1.1. Thyroid cancer survival trends by type, stage and sex: number at risk and net survival probabilities, 2004-2024

			Males				Females			
				Net Survival Probability				Net Survival Probability		
Type	Period	Stage	N at risk	1-y (95%CI)	3-y (95%CI)	5-y (95%CI)	N at risk	1-y (95%CI)	3-y (95%CI)	5-y (95%CI)
Papillary carcinoma <55y	**2004-2009**	All	432	99.8% (99.2%; 100.4%)	99.3% (98.1%; 100.5%)	99.4% (98.0%; 100.9%)	1,604	100.0% (99.7%; 100.2%)	100.0% (99.7%; 100.4%)	99.8% (99.3%; 100.3%)
		I	237	100.0% (100.0%; 100.0%)	99.5% (98.0%; 100.9%)	99.4% (97.7%; 101.1%)	930	99.9% (99.6%; 100.2%)	100.1% (99.8%; 100.5%)	99.6% (98.9%; 100.3%)
		II	19	N<50	N<50	N<50	71	100.0% (100.0%; 100.0%)	100.0% (100.0%; 100.0%)	100.0% (100.0%; 100.0%)
		III	32	N<50	N<50	N<50	65	100.0% (100.0%; 100.0%)	98.8% (95.9%; 101.8%)	96.7% (91.7%; 102.0%)
		IV	10	N<50	N<50	N<50	23	N<50	N<50	N<50
		X/NA	134	98.8% (96.7%; 100.9%)	98.6% (96.1%; 101.2%)	99.1% (96.2%; 102.1%)	515	100.0% (99.6%; 100.3%)	100.0% (99.5%; 100.6%)	100.6% (100.1%; 101.1%)
	2010-2014	All	445	99.3% (98.5%; 100.2%)	99.2% (98.0%; 100.4%)	99.7% (98.5%; 101.0%)	1,785	99.8% (99.5%; 100.1%)	99.8% (99.4%; 100.2%)	99.8% (99.3%; 100.3%)
		I	315	100.0% (100.0%; 100.0%)	99.7% (98.6%; 100.8%)	100.0% (98.8%; 101.3%)	1,444	99.7% (99.4%; 100.0%)	99.8% (99.4%; 100.2%)	99.9% (99.5%; 100.4%)
		II	23	N<50	N<50	N<50	73	100.0% (100.0%; 100.0%)	100.7% (100.7%; 100.7%)	98.5% (94.7%; 102.4%)
		III	35	N<50	N<50	N<50	74	100.0% (100.0%; 100.0%)	99.0% (96.4%; 101.7%)	99.8% (97.1%; 102.4%)
		IV	21	N<50	N<50	N<50	28	N<50	N<50	N<50
		X/NA	51	100.0% (100.0%; 100.0%)	100.3% (100.3%; 100.3%)	101.3% (101.3%; 101.3%)	166	100.0% (100.0%; 100.0%)	99.2% (97.6%; 100.9%)	99.0% (97.0%; 101.1%)
	2015-2019	All	482	99.4% (98.5%; 100.2%)	99.2% (98.2%; 100.3%)	98.4% (96.9%; 100.0%)	1,820	99.8% (99.5%; 100.1%)	99.7% (99.4%; 100.1%)	99.6% (99.1%; 100.1%)
		I	421	99.2% (98.3%; 100.2%)	99.2% (98.1%; 100.4%)	98.6% (97.1%; 100.2%)	1,677	99.8% (99.6%; 100.1%)	99.7% (99.3%; 100.1%)	99.6% (99.1%; 100.1%)

			Males				Females			
				Net Survival Probability				Net Survival Probability		
Type	Period	Stage	N at risk	1-y (95%CI)	3-y (95%CI)	5-y (95%CI)	N at risk	1-y (95%CI)	3-y (95%CI)	5-y (95%CI)
		II	20	N<50	N<50	N<50	34	N<50	N<50	N<50
		III	14	N<50	N<50	N<50	40	N<50	N<50	N<50
		IV	12	N<50	N<50	N<50	9	N<50	N<50	N<50
		X/NA	15	N<50	N<50	N<50	60	100.0% (100.0%; 100.0%)	100.0% (100.0%; 100.0%)	100.0% (100.0%; 100.0%)
	2020-2024	All	491	99.7% (99.2%; 100.3%)	99.8% (99.0%; 100.7%)	100.0% (98.8%; 101.2%)	1,770	99.9% (99.7%; 100.1%)	99.9% (99.6%; 100.2%)	99.7% (99.1%; 100.3%)
		I	482	99.7% (99.2%; 100.3%)	100.0% (99.3%; 100.8%)	100.2% (99.0%; 101.3%)	1,748	99.9% (99.7%; 100.1%)	99.9% (99.6%; 100.3%)	99.9% (99.3%; 100.4%)
		II	7	N<50	N<50	N<50	8	N<50	N<50	N<50
		X/NA	2	N<50	N<50	N<50	14	N<50	N<50	N<50
Papillary carcinoma 55+y	**2004-2009**	All	328	96.4% (93.8%; 99.1%)	94.0% (90.0%; 98.2%)	93.2% (87.9%; 98.7%)	845	98.0% (96.7%; 99.3%)	97.3% (95.3%; 99.3%)	98.3% (95.9%; 100.7%)
		I	93	100.0% (97.0%; 103.0%)	101.0% (96.1%; 106.1%)	105.3% (99.1%; 111.8%)	325	99.6% (98.3%; 100.8%)	101.0% (98.9%; 103.1%)	103.0% (100.3%; 105.8%)
		II	32	N<50	N<50	N<50	77	100.0% (100.0%; 100.0%)	97.0% (90.9%; 103.6%)	99.3% (91.9%; 107.3%)
		III	60	98.5% (94.0%; 103.3%)	99.0% (91.7%; 107.0%)	98.7% (89.1%; 109.3%)	96	96.2% (91.7%; 100.8%)	96.1% (90.1%; 102.4%)	92.1% (83.9%; 101.2%)
		IV	51	92.0% (83.2%; 101.7%)	71.4% (58.0%; 88.0%)	63.2% (46.7%; 85.5%)	63	81.7% (72.0%; 92.7%)	74.9% (62.0%; 90.6%)	77.8% (64.0%; 94.5%)
		X/NA	92	91.3% (84.9%; 98.1%)	90.0% (82.2%; 98.6%)	88.3% (78.8%; 98.9%)	284	98.5% (96.5%; 100.6%)	97.3% (94.3%; 100.5%)	97.7% (93.8%; 101.7%)
	2010-2014	All	419	96.3% (94.0%; 98.6%)	93.8% (90.3%; 97.5%)	94.3% (90.0%; 98.8%)	1,106	97.9% (96.7%; 99.0%)	98.0% (96.4%; 99.6%)	99.2% (97.1%; 101.3%)
		I	208	98.6% (96.3%; 100.9%)	99.8% (96.3%; 103.3%)	101.8% (97.6%; 106.2%)	653	99.4% (98.4%; 100.4%)	100.5% (98.9%; 102.0%)	101.0% (98.9%; 103.2%)
		II	37	N<50	N<50	N<50	99	98.0% (94.7%; 101.5%)	98.0% (94.7%; 101.5%)	101.6% (98.1%; 105.2%)
		III	74	98.0% (93.6%; 102.7%)	87.2% (77.7%; 97.8%)	84.5% (73.3%; 97.4%)	148	100.4% (98.5%; 102.3%)	101.6% (98.2%; 105.2%)	100.8% (95.4%; 106.5%)
		IV	55	81.1% (70.6%; 93.1%)	73.3% (60.3%; 89.0%)	67.5% (52.7%; 86.6%)	85	86.3% (78.6%; 94.9%)	76.3% (66.0%; 88.3%)	75.5% (64.6%; 88.2%)
		X/NA	45	N<50	N<50	N<50	121	92.5% (87.4%; 98.0%)	91.3% (84.8%; 98.2%)	93.7% (85.6%; 102.7%)
	2015-2019	All	527	97.5% (95.7%; 99.4%)	96.4% (93.5%; 99.3%)	94.5% (90.7%; 98.5%)	1,228	98.8% (97.9%; 99.7%)	99.3% (97.9%; 100.6%)	99.4% (97.5%; 101.3%)
		I	311	100.3% (98.7%; 101.9%)	100.7% (97.7%; 103.7%)	100.6% (96.4%; 105.1%)	851	100.4% (99.8%; 100.9%)	101.4% (100.4%; 102.4%)	102.8% (101.2%; 104.4%)
		II	90	97.2% (92.8%; 101.8%)	95.2% (89.1%; 101.7%)	91.5% (82.8%; 101.0%)	178	98.4% (95.8%; 101.1%)	98.2% (94.6%; 102.0%)	94.8% (89.4%; 100.5%)

			Males				Females			
				Net Survival Probability				Net Survival Probability		
Type	Period	Stage	N at risk	1-y (95%CI)	3-y (95%CI)	5-y (95%CI)	N at risk	1-y (95%CI)	3-y (95%CI)	5-y (95%CI)
		III	49	N<50	N<50	N<50	97	98.2% (94.8%; 101.8%)	98.6% (93.6%; 103.8%)	100.3% (92.3%; 109.1%)
		IV	48	N<50	N<50	N<50	48	N<50	N<50	N<50
		X/NA	29	N<50	N<50	N<50	54	94.6% (87.8%; 102.0%)	88.7% (78.1%; 100.8%)	86.1% (73.5%; 100.9%)
	2020-2024	All	538	99.8% (98.4%; 101.1%)	97.5% (94.5%; 100.5%)	98.0% (93.5%; 102.7%)	1,120	98.8% (97.9%; 99.8%)	98.9% (97.3%; 100.4%)	99.2% (96.7%; 101.8%)
		I	381	100.2% (99.0%; 101.5%)	100.0% (97.2%; 103.0%)	100.7% (95.7%; 106.0%)	886	99.8% (99.0%; 100.6%)	100.1% (98.7%; 101.6%)	101.6% (99.5%; 103.8%)
		II	112	101.3% (99.6%; 103.1%)	97.2% (90.5%; 104.3%)	95.9% (86.4%; 106.5%)	171	97.6% (94.6%; 100.7%)	97.3% (92.3%; 102.5%)	94.7% (85.8%; 104.4%)
		III	13	N<50	N<50	N<50	21	N<50	N<50	N<50
		IV	18	N<50	N<50	N<50	22	N<50	N<50	N<50
		X/NA	14	N<50	N<50	N<50	20	N<50	N<50	N<50
Follicular carcinoma <55y	**2004-2009**	All	88	100.0% (100.0%; 100.0%)	99.2% (97.0%; 101.5%)	100.1% (97.9%; 102.4%)	213	100.0% (100.0%; 100.0%)	98.0% (96.0%; 100.0%)	98.1% (96.1%; 100.2%)
		I	33	N<50	N<50	N<50	119	100.0% (100.0%; 100.0%)	98.5% (96.2%; 100.9%)	98.6% (96.4%; 101.0%)
		II	20	N<50	N<50	N<50	18	N<50	N<50	N<50
		III	9	N<50	N<50	N<50	17	N<50	N<50	N<50
		IV	4	N<50	N<50	N<50	6	N<50	N<50	N<50
		X/NA	22	N<50	N<50	N<50	53	100.0% (100.0%; 100.0%)	100.0% (100.0%; 100.0%)	100.0% (100.0%; 100.0%)
	2010-2014	All	62	98.5% (95.4%; 101.7%)	97.1% (92.8%; 101.6%)	97.7% (93.4%; 102.2%)	196	100.1% (100.1%; 100.1%)	99.3% (97.9%; 100.7%)	97.6% (95.2%; 100.1%)
		I	38	N<50	N<50	N<50	118	100.0% (100.0%; 100.0%)	100.0% (100.0%; 100.0%)	99.6% (97.9%; 101.3%)
		II	8	N<50	N<50	N<50	27	N<50	N<50	N<50
		III	4	N<50	N<50	N<50	20	N<50	N<50	N<50
		IV	2	N<50	N<50	N<50	5	N<50	N<50	N<50
		X/NA	10	N<50	N<50	N<50	26	N<50	N<50	N<50
	2015-2019	All	73	100.0% (100.0%; 100.0%)	99.1% (96.5%; 101.8%)	98.4% (94.7%; 102.3%)	201	99.1% (97.8%; 100.5%)	98.3% (96.4%; 100.3%)	98.1% (96.0%; 100.4%)
		I	58	100.0% (100.0%; 100.0%)	98.7% (95.4%; 102.1%)	98.7% (95.4%; 102.1%)	159	98.8% (97.1%; 100.6%)	98.3% (96.2%; 100.5%)	98.0% (95.6%; 100.5%)

			Males				Females			
				Net Survival Probability				Net Survival Probability		
Type	**Period**	**Stage**	**N at risk**	**1-y (95%CI)**	**3-y (95%CI)**	**5-y (95%CI)**	**N at risk**	**1-y (95%CI)**	**3-y (95%CI)**	**5-y (95%CI)**
		II	1	N<50	N<50	N<50	18	N<50	N<50	N<50
		III	9	N<50	N<50	N<50	1	N<50	N<50	N<50
		X/NA	5	N<50	N<50	N<50	21	N<50	N<50	N<50
	2020-2024	All	61	96.9% (92.6%; 101.5%)	93.7% (87.3%; 100.5%)	91.6% (83.9%; 100.0%)	174	100.0% (100.0%; 100.0%)	100.4% (100.4%; 100.4%)	99.7% (97.8%; 101.7%)
		I	53	96.4% (91.5%; 101.6%)	94.5% (88.1%; 101.4%)	92.1% (84.0%; 101.0%)	149	100.0% (100.0%; 100.0%)	100.4% (100.4%; 100.4%)	100.7% (100.7%; 100.7%)
		II	1	N<50	N<50	N<50	3	N<50	N<50	N<50
		X/NA	7	N<50	N<50	N<50	22	N<50	N<50	N<50
	2015-2019	IV					2	N<50	N<50	N<50
Follicular carcinoma 55+y	**2004-2009**	All	112	96.3% (91.8%; 101.0%)	89.7% (81.9%; 98.3%)	85.5% (75.7%; 96.5%)	206	93.0% (89.1%; 97.1%)	89.3% (83.9%; 95.0%)	83.4% (76.7%; 90.7%)
		I	13	N<50	N<50	N<50	32	N<50	N<50	N<50
		II	10	N<50	N<50	N<50	34	N<50	N<50	N<50
		III	39	N<50	N<50	N<50	47	N<50	N<50	N<50
		IV	25	N<50	N<50	N<50	34	N<50	N<50	N<50
		X/NA	25	N<50	N<50	N<50	59	88.2% (79.7%; 97.6%)	87.0% (76.9%; 98.4%)	84.9% (72.9%; 99.0%)
	2010-2014	All	110	99.3% (95.4%; 103.4%)	92.5% (84.1%; 101.8%)	87.5% (76.8%; 99.6%)	174	95.6% (92.0%; 99.4%)	92.1% (86.3%; 98.2%)	85.3% (77.7%; 93.6%)
		I	9	N<50	N<50	N<50	31	N<50	N<50	N<50
		II	28	N<50	N<50	N<50	31	N<50	N<50	N<50
		III	36	N<50	N<50	N<50	51	98.9% (95.1%; 102.9%)	101.7% (96.1%; 107.6%)	101.6% (92.7%; 111.3%)
		IV	20	N<50	N<50	N<50	43	N<50	N<50	N<50
		X/NA	17	N<50	N<50	N<50	18	N<50	N<50	N<50
	2015-2019	All	123	95.6% (91.2%; 100.1%)	89.1% (81.6%; 97.3%)	88.9% (79.8%; 99.0%)	194	94.2% (90.3%; 98.3%)	91.1% (85.4%; 97.1%)	87.0% (79.1%; 95.8%)
		I	33	N<50	N<50	N<50	64	100.0% (100.0%; 100.0%)	100.0% (100.0%; 100.0%)	100.9% (92.4%; 110.2%)
		II	29	N<50	N<50	N<50	66	96.3% (90.5%; 102.5%)	95.6% (87.5%; 104.4%)	92.0% (80.1%; 105.8%)

			Males				Females			
				Net Survival Probability				Net Survival Probability		
Type	Period	Stage	N at risk	1-y (95%CI)	3-y (95%CI)	5-y (95%CI)	N at risk	1-y (95%CI)	3-y (95%CI)	5-y (95%CI)
		III	21	N<50	N<50	N<50	17	N<50	N<50	N<50
		IV	22	N<50	N<50	N<50	29	N<50	N<50	N<50
		X/NA	18	N<50	N<50	N<50	18	N<50	N<50	N<50
	2020-2024	All	187	95.6% (92.0%; 99.2%)	93.7% (88.0%; 99.8%)	95.7% (88.3%; 103.8%)	227	96.5% (93.4%; 99.6%)	94.4% (89.3%; 99.9%)	84.4% (73.4%; 96.9%)
		I	66	98.0% (93.9%; 102.2%)	95.3% (87.2%; 104.2%)	101.5% (92.9%; 111.0%)	112	98.9% (96.3%; 101.5%)	100.2% (95.3%; 105.4%)	99.2% (91.0%; 108.2%)
		II	83	98.5% (94.4%; 102.7%)	97.1% (89.3%; 105.6%)	96.4% (85.3%; 109.0%)	57	99.1% (94.3%; 104.1%)	96.2% (85.5%; 108.1%)	76.9% (52.7%; 112.0%)
		III	4	N<50	N<50	N<50	4	N<50	N<50	N<50
		IV	25	N<50	N<50	N<50	33	N<50	N<50	N<50
		X/NA	9	N<50	N<50	N<50	21	N<50	N<50	N<50
Medullary carcinoma	**2004-2009**	All	94	96.4% (91.9%; 101.1%)	90.7% (83.8%; 98.2%)	86.9% (77.9%; 96.9%)	121	89.2% (83.7%; 95.2%)	88.5% (82.4%; 95.1%)	83.9% (76.5%; 92.0%)
		I	15	N<50	N<50	N<50	33	N<50	N<50	N<50
		II	8	N<50	N<50	N<50	12	N<50	N<50	N<50
		III	15	N<50	N<50	N<50	12	N<50	N<50	N<50
		IV	28	N<50	N<50	N<50	25	N<50	N<50	N<50
		X/NA	28	N<50	N<50	N<50	39	N<50	N<50	N<50
	2010-2014	All	74	90.7% (83.8%; 98.2%)	87.1% (77.8%; 97.4%)	78.1% (65.5%; 93.1%)	106	95.3% (91.0%; 99.9%)	94.8% (89.5%; 100.4%)	93.8% (87.8%; 100.2%)
		I	13	N<50	N<50	N<50	40	N<50	N<50	N<50
		II	11	N<50	N<50	N<50	20	N<50	N<50	N<50
		III	9	N<50	N<50	N<50	8	N<50	N<50	N<50
		IV	34	N<50	N<50	N<50	22	N<50	N<50	N<50
		X/NA	7	N<50	N<50	N<50	16	N<50	N<50	N<50
	2015-2019	All	70	98.8% (94.9%; 102.9%)	86.0% (76.7%; 96.4%)	81.2% (67.7%; 97.5%)	86	98.9% (95.7%; 102.3%)	94.0% (87.6%; 100.7%)	93.8% (86.4%; 101.9%)
		I	16	N<50	N<50	N<50	39	N<50	N<50	N<50

			Males				Females			
				Net Survival Probability				Net Survival Probability		
Type	Period	Stage	N at risk	1-y (95%CI)	3-y (95%CI)	5-y (95%CI)	N at risk	1-y (95%CI)	3-y (95%CI)	5-y (95%CI)
		II	10	N<50	N<50	N<50	12	N<50	N<50	N<50
		III	13	N<50	N<50	N<50	8	N<50	N<50	N<50
		IV	27	N<50	N<50	N<50	21	N<50	N<50	N<50
		X/NA	4	N<50	N<50	N<50	6	N<50	N<50	N<50
	2020-2024	All	79	98.6% (95.2%; 102.3%)	96.2% (89.1%; 103.8%)	88.3% (75.3%; 103.6%)	122	97.5% (94.3%; 100.7%)	98.7% (94.7%; 102.9%)	96.4% (88.7%; 104.6%)
		I	19	N<50	N<50	N<50	53	100.0% (100.0%; 100.0%)	104.4% (104.4%; 104.4%)	102.4% (92.0%; 114.0%)
		II	13	N<50	N<50	N<50	17	N<50	N<50	N<50
		III	8	N<50	N<50	N<50	16	N<50	N<50	N<50
		IV	37	N<50	N<50	N<50	35	N<50	N<50	N<50
		X/NA	2	N<50	N<50	N<50	1	N<50	N<50	N<50
Anaplastic carcinoma	**2004-2009**	All	63	21.0% (13.0%; 33.9%)	16.4% (9.4%; 28.7%)	10.3% (4.9%; 21.6%)	94	15.3% (9.6%; 24.6%)	6.6% (3.1%; 14.0%)	4.6% (1.8%; 11.6%)
		X/NA	3	N<50	N<50	N<50	5	N<50	N<50	N<50
	2010-2014	All	47	N<50	N<50	N<50	71	14.8% (8.5%; 25.7%)	10.3% (5.0%; 21.2%)	6.5% (2.2%; 19.4%)
		X/NA	5	N<50	N<50	N<50	7	N<50	N<50	N<50
	2015-2019	All	42	N<50	N<50	N<50	66	21.7% (13.8%; 34.3%)	13.6% (7.3%; 25.4%)	10.2% (4.9%; 21.3%)
		X/NA	6	N<50	N<50	N<50	7	N<50	N<50	N<50
	2020-2024	All	59	32.8% (22.8%; 47.2%)	23.0% (14.3%; 37.0%)	21.9% (12.9%; 37.0%)	64	17.6% (10.3%; 30.0%)	8.9% (4.0%; 19.9%)	9.0% (4.1%; 20.1%)
		X/NA	4	N<50	N<50	N<50	4	N<50	N<50	N<50
Other	**2004-2009**	All	27	N<50	N<50	N<50	52	68.0% (56.3%; 82.2%)	62.0% (49.6%; 77.6%)	58.4% (45.4%; 75.3%)
		I	1	N<50	N<50	N<50	3	N<50	N<50	N<50
		III	3	N<50	N<50	N<50	3	N<50	N<50	N<50
		IV	8	N<50	N<50	N<50	6	N<50	N<50	N<50
		X/NA	15	N<50	N<50	N<50	36	N<50	N<50	N<50

			Males				Females			
				Net Survival Probability				Net Survival Probability		
Type	Period	Stage	N at risk	1-y (95%CI)	3-y (95%CI)	5-y (95%CI)	N at risk	1-y (95%CI)	3-y (95%CI)	5-y (95%CI)
	2010-2014	All	33	N<50	N<50	N<50	56	66.6% (55.3%; 80.3%)	53.4% (41.5%; 68.6%)	51.7% (39.8%; 67.0%)
		I	4	N<50	N<50	N<50	15	N<50	N<50	N<50
		II	3	N<50	N<50	N<50	3	N<50	N<50	N<50
		III	4	N<50	N<50	N<50	2	N<50	N<50	N<50
		IV	10	N<50	N<50	N<50	12	N<50	N<50	N<50
		X/NA	12	N<50	N<50	N<50	24	N<50	N<50	N<50
	2015-2019	All	22	N<50	N<50	N<50	80	63.3% (53.4%; 75.0%)	56.4% (46.1%; 69.0%)	56.4% (45.2%; 70.3%)
		I	2	N<50	N<50	N<50	16	N<50	N<50	N<50
		II	7	N<50	N<50	N<50	6	N<50	N<50	N<50
		III	1	N<50	N<50	N<50	3	N<50	N<50	N<50
		IV	7	N<50	N<50	N<50	26	N<50	N<50	N<50
		X/NA	5	N<50	N<50	N<50	29	N<50	N<50	N<50
	2020-2024	All	36	N<50	N<50	N<50	55	79.0% (68.6%; 91.0%)	74.8% (62.5%; 89.6%)	65.7% (50.8%; 85.0%)
		I	8	N<50	N<50	N<50	23	N<50	N<50	N<50
		II	7	N<50	N<50	N<50	5	N<50	N<50	N<50
		III	1	N<50	N<50	N<50	1	N<50	N<50	N<50
		IV	10	N<50	N<50	N<50	11	N<50	N<50	N<50
		X/NA	10	N<50	N<50	N<50	15	N<50	N<50	N<50
	2004-2009	II					4	N<50	N<50	N<50

Note: Survival results obtained on very small groups are considered to be too uncertain, therefore a minimum size threshold of 50 is applied in the reporting of the Net Survival estimation.

6.1. Thyroid cancer mortality: by region

6.1.1. Thyroid cancer mortality by region and sex: number of cancer deaths, age-specific, crude and age-standardised mortality rates, 2023*

	N [CR]																				ESR2013 (95%CI)
Region	**0-**	**5-**	**10-**	**15-**	**20-**	**25-**	**30-**	**35-**	**40-**	**45-**	**50-**	**55-**	**60-**	**65-**	**70-**	**75-**	**80-**	**85-**	**90-**	**95-**	**All ages**	
Males																						
Belgium	0	0	0	0	0	0	0	0	0	0	0	2	7	8	4	9	4	6	4	0	44	0.8
	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.5]	[1.9]	[2.5]	[1.5]	[4.4]	[3.2]	[7.5]	[12.8]	[0.0]	[0.8]	(0.6; 1.1)
Brussels	0	0	0	0	0	0	0	0	0	0	0	1	1	0	0	0	0	1	0	0	3	0.7
	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[2.8]	[3.5]	[0.0]	[0.0]	[0.0]	[0.0]	[20.0]	[0.0]	[0.0]	[0.5]	(0.0; 1.5)
Flanders	0	0	0	0	0	0	0	0	0	0	0	1	5	6	3	6	2	5	3	0	31	0.9
	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.4]	[2.2]	[3.1]	[1.8]	[4.6]	[2.4]	[9.3]	[14.4]	[0.0]	[0.9]	(0.6; 1.2)
Wallonia	0	0	0	0	0	0	0	0	0	0	0	0	1	2	1	3	2	0	1	0	10	0.7
	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.9]	[2.0]	[1.2]	[5.0]	[5.8]	[0.0]	[12.2]	[0.0]	[0.6]	(0.2; 1.1)
Females																						
Belgium	0	0	0	0	0	0	0	0	0	0	0	1	2	1	11	7	14	6	3	1	46	0.7
	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.3]	[0.5]	[0.3]	[3.7]	[2.8]	[8.0]	[4.5]	[4.2]	[4.8]	[0.8]	(0.5; 0.9)
Brussels	0	0	0	0	0	0	0	0	0	0	0	0	0	0	2	0	2	0	0	0	4	0.9
	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[9.3]	[0.0]	[15.6]	[0.0]	[0.0]	[0.0]	[0.6]	(0.0; 1.7)

Region	N [CR] 0-	5-	10-	15-	20-	25-	30-	35-	40-	45-	50-	55-	60-	65-	70-	75-	80-	85-	90-	95-	All ages	ESR2013 (95%CI)
Flanders	0	0	0	0	0	0	0	0	0	0	0	0	2	1	7	5	9	6	2	0	32	0.8
	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.9]	[0.5]	[4.0]	[3.3]	[8.2]	[7.0]	[4.5]	[0.0]	[0.9]	(0.5; 1.0)
Wallonia	0	0	0	0	0	0	0	0	0	0	0	1	0	0	2	2	3	0	1	1	10	0.5
	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.8]	[0.0]	[0.0]	[2.0]	[2.6]	[5.8]	[0.0]	[4.7]	[15.4]	[0.5]	(0.2; 0.8)

7.1. Thyroid cancer mortality trends: by region

7.1.1. Thyroid cancer mortality trends in males, by region: number of cancer deaths, crude and age-standardised mortality rates, including average annual percentage change, 2004-2023*

Region		2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	AAPC, % (95%CI)	Period
Belgium	**N**	27	25	26	24	33	33	33	35	40	33	17	29	30	25	37	33	19	35	32	44		
	CR	0.5	0.5	0.5	0.5	0.6	0.6	0.6	0.7	0.7	0.6	0.3	0.5	0.5	0.4	0.7	0.6	0.3	0.6	0.6	0.8		
	ESR2013	0.7	0.7	0.6	0.6	0.8	0.7	0.8	0.8	0.9	0.8	0.4	0.6	0.7	0.5	0.8	0.6	0.4	0.7	0.6	0.8	-0.5 (-2.5; 1.5)	2004-2023
Brussels	**N**	3	0	1	1	1	2	4	1	2	1	1	2	3	3	3	2	3	2	3	3		
	CR	0.6	0.0	0.2	0.2	0.2	0.4	0.8	0.2	0.4	0.2	0.2	0.3	0.5	0.5	0.5	0.3	0.5	0.3	0.5	0.5		
	ESR2013	0.9	0.0	0.3	0.3	0.3	0.6	1.1	0.2	0.5	0.2	0.3	0.5	0.9	0.9	0.8	0.6	0.8	0.7	0.6	0.7	NA	2004-2023
Flanders	**N**	15	19	16	16	20	25	15	25	26	24	11	21	20	12	22	19	13	21	21	31		
	CR	0.5	0.6	0.5	0.5	0.7	0.8	0.5	0.8	0.8	0.8	0.3	0.7	0.6	0.4	0.7	0.6	0.4	0.6	0.6	0.9		
	ESR2013	0.6	0.8	0.6	0.6	0.8	0.9	0.6	1.0	1.0	0.9	0.4	0.7	0.8	0.4	0.7	0.6	0.4	0.7	0.6	0.9	-0.8 (-3.2; 1.6)	2004-2023
Wallonia	**N**	9	6	9	7	12	6	14	9	12	8	5	6	7	10	12	12	3	12	8	10		
	CR	0.5	0.4	0.5	0.4	0.7	0.4	0.8	0.5	0.7	0.5	0.3	0.3	0.4	0.6	0.7	0.7	0.2	0.7	0.4	0.6		
	ESR2013	0.7	0.6	0.6	0.5	0.9	0.4	1.0	0.6	0.9	0.6	0.3	0.5	0.5	0.7	0.8	0.8	0.2	0.8	0.6	0.7	-1.2 (-4.6; 2.4)	2004-2023

Note: In case a change in trend is detected, an estimated APC per time segment is given as well as Average Annual Percentage Change (AAPC) for the entire incidence period.

7.1.2. Thyroid cancer mortality trends in females, by region: number of cancer deaths, crude and age-standardised mortality rates, including average annual percentage change, 2004-2023*

Region		2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	AAPC, % (95%CI)	Period
Belgium	**N**	48	51	45	44	45	51	47	54	54	41	51	46	37	29	52	41	46	35	49	46		
	CR	0.9	1.0	0.8	0.8	0.8	0.9	0.9	1.0	1.0	0.7	0.9	0.8	0.6	0.5	0.9	0.7	0.8	0.6	0.8	0.8		
	ESR2013	0.9	0.9	0.8	0.8	0.8	0.9	0.8	1.0	0.9	0.7	0.8	0.8	0.6	0.5	0.8	0.6	0.7	0.5	0.7	0.7	-2.1 (-3.4; -0.9)	2004-2023
Brussels	**N**	4	4	8	2	3	4	1	5	5	3	3	4	2	2	1	3	4	2	6	4		
	CR	0.8	0.8	1.5	0.4	0.6	0.7	0.2	0.9	0.9	0.5	0.5	0.7	0.3	0.3	0.2	0.5	0.6	0.3	1.0	0.6		
	ESR2013	0.7	0.7	1.9	0.4	0.6	0.8	0.2	0.9	1.2	0.7	0.5	0.9	0.4	0.3	0.1	0.5	0.7	0.3	1.1	0.9	-2.0 (-6.9; 3.0)	2004-2023
Flanders	**N**	27	34	20	28	34	31	26	36	37	23	39	30	24	20	37	28	32	25	37	32		
	CR	0.9	1.1	0.6	0.9	1.1	1.0	0.8	1.1	1.2	0.7	1.2	0.9	0.7	0.6	1.1	0.8	1.0	0.7	1.1	0.9		
	ESR2013	0.9	1.1	0.6	0.8	1.0	0.9	0.7	1.1	1.0	0.6	1.0	0.8	0.6	0.5	0.9	0.7	0.7	0.6	0.9	0.8	-1.3 (-2.9; 0.4)	2004-2023
Wallonia	**N**	17	13	17	14	8	16	20	13	12	15	9	12	11	7	14	10	10	8	6	10		
	CR	1.0	0.7	1.0	0.8	0.4	0.9	1.1	0.7	0.7	0.8	0.5	0.7	0.6	0.4	0.8	0.5	0.5	0.4	0.3	0.5		
	ESR2013	0.9	0.7	1.0	0.8	0.4	1.0	1.0	0.7	0.6	0.8	0.4	0.6	0.5	0.3	0.7	0.4	0.5	0.4	0.2	0.5	-4.4 (-6.7; -2.2)	2004-2023

Note: In case a change in trend is detected, an estimated APC per time segment is given as well as Average Annual Percentage Change (AAPC) for the entire incidence period.

*Mortality statistics in Belgium are collected and managed by the three Regions (Flemish Region: Departement Zorg; Brussels-Capital Region: Observatorium voor Gezondheid en Welzijn van Brussel-Hoofdstad/ l'Observatoire de la Santé et du Social de Bruxelles-Capitale; Walloon Region: Agence Wallonne de la Santé, de la Protection sociale, du Handicap et des Familles (AVIQ)). The Directorate General Statistics Belgium is responsible for collecting and merging the data coming from the regional agencies. Mortality data used in this cancer fact sheet are collected from the Directorate General Statistics Belgium and encompasses the period 2004-2023.

Recommended reference: Cancer Fact Sheets 2024, Belgian Cancer Registry (BCR), 2026